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Viruses are usually described as non-living objects because they lack in-
dependent metabolism and therefore require living cells for procreation. 
Usually, though not always, viral infection is harmful for cells and can even 
result in cell death. Although there is no direct correlation between the cyto-
toxicity of a virus and its in vivo pathogenicity, the same also applies at the 
level of the organism: viral infection disturbs numerous processes within the 
organism and activates various defense reactions that in combination with other 
factors, may lead to sickness and death of the organism. For this reason, viruses 
capable of infecting humans are often medically important pathogens. On the 
other hand, both killing of cells and the activation of defense reactions of cells 
and organisms by viruses provide researchers with the opportunity to use 
viruses and virus-based vectors to treat various genetic disorders and as anti-
cancer agents.  
Alphaviruses are small positive-strand RNA viruses that make up the genus 
Alphavirus of the family Togaviridae. The species of the genus are rather 
numerous and genetically diverse. The type member of the genus is Sindbis 
virus (SINV); other well-studied members of the genus include Semliki Forest 
virus (SFV) (Strauss and Strauss, 1994) and, more recently, Venezuelan equine 
encephalitis virus (VEEV) and Chikungunya virus (CHIKV). Alphaviruses 
infect a large variety of cell types within organisms. This property makes it 
possible to use these viruses to develop replication-competent vectors that may 
have clinical applications. However, as with many other viruses, the potential 
for creating clinically useful vectors can only be exploited if virus replication 
and gene expression are subject to a certain level of control. This is challenging 
because, on the one hand, wild-type (wt) alphaviruses often cause serious 
diseases. On the other hand genetically modified viruses are often too severely 
attenuated to represent potent tools against rapidly growing cancers. Finally, all 
modified viruses display a tendency to revert to their wt forms. 
This thesis is focused on the development of novel types of SFV-based 
vectors. For this, a novel DNA/RNA layered system capable of producing 
infectious RNAs inside transfected cells was developed. Subsequently, the 
corresponding vectors were engineered to contain different control systems. 
First, a system based on the use of aberrantly spliced introns and the rescue of 
corresponding defects using splice-switch oligonucleotides (SSOs) was 
developed. Second, the target sites of host micro RNAs (miRNAs) were used to 
down-regulate viral infectivity, replication and gene expression. The properties 
of both types of vectors were characterized using various cell-culture-based 
assays, which revealed the potential of such vectors but also highlighted 
problems associated with the use of these control systems. 
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REVIEW OF LITERATURE 
 
Alphaviruses 
The family Togaviridae, which includes the genera Alphavirus and Rubivirus, 
contains small viruses with enveloped virions and positive-strand non-segmented 
RNA genomes. The genus Alphavirus contains approximately 30 recognized 
members. The proteins encoded by different alphaviruses are characterized by 
similarities in the amino acid (aa) sequences: approximately 60% similarity is 
observed for non-structural (ns) proteins, and at least 45% similarity exists for 
structural proteins (Strauss and Strauss, 1994; Luers et al., 2005). 
Alphaviruses are distributed worldwide. Those that infect birds and mammals 
can be divided into Old World and New World subgroups. The New World 
alphaviruses are VEEV and Western (WEEV) and Eastern (EEEV) equine 
encephalitis virus. The Old World alphavirus subgroup includes SFV, SINV and 
CHIKV, as well as many others (Strauss and Strauss, 1994). With the exception 
of species that infect fish, all alphaviruses are spread by arthropod vectors, usually 
mosquitoes. Infection of the arthropod vector is not associated with visible 
pathology and is therefore considered asymptomatic. Alphaviruses can also infect 
vertebrates, including humans. Similar to infections caused by other arboviruses, 
alphavirus infection in vertebrates is characterized by high-titer viremia, which is 
essential to ensure vector transmission – an essential phase in the natural life 
cycle of the virus. In addition, infection in humans is often associated with 
illnesses such as rash, arthritis or encephalitis (Aguilar et al., 2011). In general, 
the primary symptoms caused by alphavirus infection are fever and headache. 
However, some New World alphaviruses, as evident from their names, can cause 
encephalitis, and mortality rates as high as 50–70% have been observed for EEEV 
(Strauss and Strauss, 1994). Viruses from the Old World subgroup are more 
likely to cause subclinical infections; even in cases of acute illness, the mortality 
rate associated with infection by these viruses is generally low. Therefore, the Old 
World alphaviruses have until recently been considered to be medically less 
important than the New World alphaviruses. This situation changed with the 
recent (2005–2007) outbreak of CHIKV, which caused a variety of medical, 
social and economic problems (Kelvin et al., 2011). On islands in the Indian 
Ocean, this epidemic resulted in millions of infected people; the associated 
mortality rate was 0.1% (Das et al., 2010; Schwartz and Albert, 2010). 
To date, the best-studied alphaviruses are SINV and SFV. In contrast to 
medically more important alphaviruses such as VEEV and CHIKV, attenuated 
laboratory strains of SFV and SINV are considered non-pathogenic to humans. 
Consequently, these viruses are used both as objects and as tools of basic 
research. The extensive knowledge obtained through the study of these viruses 
has been used to characterize other alphaviruses (although in some cases this 
has led to erroneous generalizations) and even to improve  understanding of 
other enveloped viruses with RNA genomes (Ellgaard and Helenius, 2003). In 
addition, alphavirus-based gene expression vectors have been found to possess 
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numerous useful properties and are therefore thought to have potential as 
therapeutic and/or anti-cancer agents (Riezebos-Brilman et al., 2006; Johansson 
et al., 2012). Alphaviruses and vectors based on these viruses have small, 
simple genomes that can be easily modified. The vectors can be used to infect 
various cell types, and high levels of foreign gene expression can often be 
achieved (Strauss and Strauss, 1994). However, like all viral vectors, alpha-
virus-based expression systems have intrinsic limitations. In general, they are 
highly cytotoxic, making them unsuitable for long-term gene expression but 
suitable for brief gene expression and the virus-mediated killing of targeted 
cells. In addition, like the vast majority of RNA replicases of RNA viruses, the 
RNA-dependent RNA polymerase (RdRp) of alphaviruses lacks proofreading 
activity. Therefore, the alphavirus replicase makes 10–3–10–5 synthesis errors 
per nucleotide per replication cycle. Coupled with the very efficient RNA 
recombination and the general growth advantages of wt viruses, this error rate 
makes modified RNA genomes of alphavirus-based vectors unstable (Rausalu et 
al., 2009). As a consequence, alphavirus vectors have an intrinsic tendency to 
eliminate inserted therapeutic genes of interest and/or to revert pathogenicity-
reducing mutations. Therefore, during their propagation, constructed alpha-
virus-based vectors often revert to wt viruses or pseudorevert to viruses with 
growth characteristics similar to those of the wt virus (Domingo et al., 1997).  
 
 
Virion and genome organization 
The alphavirus virion has icosahedral symmetry, and its diameter is 65–70 nm. 
The genome is located inside the virion and consists of a single molecule of 
single-stranded RNA. The genome is surrounded by 240 copies of the viral 
capsid protein (C), which form a coat termed the capsid. Capsid together with 
genome is termed nucleocapsid (NC), has a diameter of 40 nm and in virions is 
covered with a host-derived lipid bilayer envelope. The alphavirus envelope 
contains 80 glycoprotein spikes, each of which is formed by three copies of 
each viral envelope protein (heterodimers of the E1 and E2 transmembrane 
proteins and, in some alphaviruses, extrinsic E3) (Cheng et al., 1995; Fuller et 
al., 1995). The outer glycoprotein layer covers most of the surface of the virion 
membrane. Together with the one-to-one molar ratio of C and membrane pro-
teins, this gives alphavirus virions a highly regular structure. 
The RNA genome of alphaviruses is approximately 11.5 kb in length. The 
genomic RNA, which in the case of SFV is historically also referred to as 42S 
RNA, is similar in structure to cellular mRNAs: it contains a cap structure at the 
5’ end and a poly(A) tail at the 3` end (Figure 1). Unlike most cellular RNAs, 
however, it contains two large open reading frames (ORFs), of which only the 
first is translated from the viral genome. For the expression of proteins encoded in 
the second ORF, an additional RNA molecule, termed ‘subgenomic’ (SG) RNA 
(also referred as 26S RNA), is produced in infected cells. SG RNA resembles 
genomic RNA in that it has the same polarity as genomic RNA and contains cap 
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and poly(A) structures, but it is shorter, being collinear to the 3’ one-third of the 
genomic RNA. Apart from different strategies for their expression, the products 
of the two different ORFs also have distinctly different functions. The first ORF, 
which represents nearly two-thirds of the alphavirus genome, encodes a ns-
polyprotein (P1234 polyprotein) that is the precursor of the ns-proteins nsP1, 
nsP2, nsP3 and nsP4, the virus-encoded subunits of the RNA replicase complex. 
The structural proteins (C, E1, E2, E3, 6K and the recently described TF protein) 
are transcribed from the second ORF in the form of a structural polyprotein by 
means of SG mRNA, which is itself generated by internal initiation of 
transcription from the SG promoter. The SG promoter is located on the third 
RNA molecule found in alphavirus-infected cells, the complementary negative-
strand RNA. This molecule is transcribed from genomic RNA and in turn serves 
as a template for both types of positive-strand RNAs. Because there are only two 
ORFs but in total ten mature proteins, both nsPs and structural proteins are 
expressed as polyprotein precursors. The conversion of these polyproteins to 
mature proteins occurs as a result of tightly controlled processing by two viral 
(nsP2, C) and several host cell proteases (Strauss and Strauss, 1994; Schlesinger 




Figure 1. Basic schema of SFV RNA synthesis, translation of genomic and SG RNAs 
and processing of ns- and structural polyproteins. For ns-polyproteins, only the early 
processing pathway leading to the formation of replicase complexes is shown. 
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In addition to its coding regions, the alphavirus genome also contains three 
relatively short untranslated regions (UTR). Two of these UTRs are located at 
the 5`and 3`ends of the genome and play important roles in viral RNA repli-
cation; the third is located between two ORFs and partially overlaps with se-
quences important for the synthesis of SG RNA (Schlesinger and Schlesinger, 
2007).   
 
Infection cycle 
Entry. All alphaviruses use membrane glycoprotein E2 as an antireceptor 
(Tucker and Griffin, 1991; Smith et al., 1995). In contrast, no cellular receptor 
common for all alphaviruses is known. Instead, various studies have identified 
different proteins as receptors for different alphaviruses; the identity of the 
receptor depends both on the virus species and on the cell type and origin (e.g., 
the vertebrate host or an insect vector) (Wang et al., 1992; Klimstra et al., 2003; 
Jose et al., 2009; Rose et al., 2011). There is also some controversy concerning 
the alphavirus entry mechanism. However, the vast majority of studies have 
shown that alphaviruses use receptor-mediated endocytosis to enter host cells. 
After the virion binds to the cell surface, clathrin-mediated endocytosis takes 
place; subsequently, the internalized virions are localized in early endosomes. 
As the endosomes mature, the pH within them decreases; after it reaches a 
critical level (for alphaviruses, pH 6 and below), conformational changes occur 
in the virion envelope proteins. One outcome of these changes is the formation 
of E1 homotrimers that act as fusion proteins to cause merging of the virion 
envelope with the endosomal membrane (Wahlberg et al., 1992; Gibbons et al., 
2000). Membrane fusion releases the viral NC to the host cell cytoplasm, where 
it is unpacked by ribosomes, resulting in release of the viral genome  within the 
cytoplasm (Salminen et al., 1992; Singh and Helenius, 1992; Smith et al., 1995; 
Vonderheit and Helenius, 2005).  
The RNA genome that has been released within the cytoplasm initiates the 
subsequent steps of infection (Figure 1). Importantly, these steps are similar or 
even identical regardless of the method of entry and the exact origin of the 
genomic RNA. This similarity is extremely useful for the experimental mani-
pulation of alphavirus vectors because it allows infection to be initiated using 
naked RNA molecules prepared using in vitro transcription or synthesized in the 
cell nucleus from delivered complementary DNA (cDNA) of the virus genome. 
Ns-protein expression and virus genome replication. The incoming virus 
genome serves as a template for the production of ns-polyprotein or poly-
proteins, depending on the presence or absence of leaky stop codon in the 
region corresponding to the C-terminus of nsP3. The full-sized P1234 contains 
over 2400 aa residues and is processed by nsP2 and/or by the corresponding 
regions of ns-polyproteins into four individual nsPs. Processing does not occur 
at random; instead, the order and timing of the cleavages are fixed. This is 
essential because the formation and activation of the viral replicase as well as 
the coordination of its functions are achieved via changes in ns-polyproteins. 
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Individually expressed nsPs fail to interact normally; cannot form structures 
characteristic of alphavirus replicase complexes (see below); and are unable to 
synthesize viral RNAs. The artificial acceleration of P1234 processing is 
reported to be detrimental for virus replication (Strauss et al., 1992). Similarly, 
slow down of P1234 processing results in different adverse effects on virus 
infectivity; the nature of defects depends on which processing sites are affected 
(Lulla et al., 2006, 2012, 2013; Gorchakov et al., 2008). Thus, the only known 
pathway for formation of functional alphavirus replicase complexes involves 
normal expression and processing of ns-polyprotein. 
P1234 processing is also associated with the formation of replicase 
complexes and with changes in their RNA substrate specificity. To form early 
replicase, P1234 must initially be cleaved between nsP3 and nsP4. This is a 
rapid reaction, and at the early stage of infection it is also the first cleavage of 
ns-polyprotein to occur (Merits et al., 2001; Lulla et al., 2006). The early 
replicase complex binds to the genomic RNA of the virus and uses it as a 
template; hence, it is responsible for the synthesis of full-length negative-strand 
RNA. This particular pattern of processing dominates only at the early stage of 
infection, which lasts for approximately 4 hours (Sawicki and Sawicki, 1980). 
Nevertheless, this amount of time is sufficient for the generation of 
approximately 20000 negative stand RNAs (anti-genomes) per cell (the exact 
number generated seems to depend on the size of the cell) (Wang et al., 1991; 
Mai et al., 2009; Frolova et al., 2010). The negative-strand RNA is comple-
mentary to the viral RNA genome except that it contains one unpaired G 
nucleotide at the 3`end and has no cap-structure at 5’ end (Sawicki and Go-
matos, 1976; Wengler et al., 1979). Early studies have shown that the negative 
strand of alphavirus RNA may also contain a poly(U) sequence that corresponds 
to a poly(A) tail. However, these findings have been challenged by more recent 
studies indicating that synthesis of negative-strand RNA is initiated imme-
diately upstream of the poly(A) sequence of the positive-strand template and, 
accordingly, negative-strand RNA must lack poly(U) (Hardy and Rice, 2005; 
Hardy, 2006). Indeed, the double-stranded RNAs that form the replication 
intermediates of alphaviruses have the ability to bind oligo(dT) resin, indicating 
that they lack a poly(U) element in the negative strand (Nikonov et al., 2013). 
There is also no indication that the negative-strand RNAs of alphaviruses exist 
as individual, single-stranded RNA molecules. Instead, negative-strand RNA 
molecules are always found in duplexes with positive-strand RNA. The only 
possible explanation for this is that each individual positive-strand RNA serves 
as a template for the synthesis of only one anti-genome. Consequently, once the 
negative strand is made, the replicase must be re-organized to carry out the 
synthesis of positive strands. Indeed, the mechanism by which this switch 
occurs has been described. Cleavage of the remaining P123 polyprotein leads to 
the formation of a late replication complex containing nsP1, nsP2, nsP3 and 
nsP4; within this complex, negative-strand RNA is used as a matrix for the 
synthesis of both genomic and SG mRNAs (Li and Rice, 1993; Lemm et al., 
1994; Griffin, 2001).  
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Unlike early replicase, the late replication complexes are capable of many 
rounds of synthesis and, once formed, remain active until the death of the host 
cell. The late replicase complexes have the appearance of membrane-bound 
vesicles, appearing as spherules with an average diameter of 50 nm. The 
spherules are formed at the plasma membrane of infected cells (Frolova et al., 
2010; Spuul et al., 2010); later in infection, they become located in structures 
termed type I cytopathic vacuoles (CPV), which represent modified endosomes 
and lysosomes (Froshauer et al., 1988; Kujala et al., 2001; Gorchakov et al., 
2008). Unless certain mutants, characterized by discontinuous synthesis of 
negative-strand RNAs, are used the spherules are formed only during the early 
stages of infection. Their formation ceases approximately 4 hours post-infection 
due to two mechanisms. First, the excess of free nsP2 protein causes changes in 
P1234 processing that prevent the formation of early and consequently also late 
replicase complexes; second, virus-induced shutdown of translation subsequent-
ly abolishes the synthesis of ns-polyprotein. Thus, while the early stages of 
alphavirus infection are characterized by the synthesis of both negative- and 
positive-strand RNAs, only the latter molecules are produced at late stages of 
infection. 
Similar to the replication of all eukaryotic positive-strand RNA viruses, the 
replication of alphaviruses occurs in membrane-bound compartments. Of the 
nsPs of alphaviruses, nsP1, which contains 537 aa, is the only membrane-
binding protein (Ahola et al., 2000; Spuul et al., 2007) and is essential for the 
binding of the alphavirus replicase complex to cytoplasmic membranes (Salo-
nen et al., 2003). Equally importantly, nsP1 has methyltransferase and guanylyl-
transferase activities, both of which are required for the addition of a cap-
structure to the alphavirus genomic and SG RNAs (Ahola and Kääriäinen, 
1995). nsP1 is also abundantly found outside of virus replication complexes. In 
infected cells, most of the free nsP1 is located at the inner surface of the plasma 
membrane, (Ahola et al., 1997) where it is responsible for the disruption and 
rearrangement of the cellular actin cytoskeleton and the induction of outgrowth 
of filopodia-like structures (Laakkonen et al., 1998; Zusinaite et al., 2007). 
nsP2, which contains 799 aa, is the largest ns-protein of alphaviruses; 
similarly, it has the largest number of known enzymatic and non-enzymatic 
activities. The C-terminal portion of nsP2, which is a papaine-like protease, is 
responsible for the autocatalytic processing of ns-polyprotein (Merits et al., 
2001). The N-terminal portion of nsP2 has functions that are important for viral 
RNA synthesis and modification. It has NTPase activity (Rikkonen et al., 1994) 
and RNA 5` triphosphatase activity; the latter contributes to the first reaction of 
synthesis of cap-structures on viral positive-strand RNA (Vasiljeva et al., 2000). 
The RNA helicase activity of nsP2 has also been thought to be associated with 
the N-terminal part of the protein; however, recent data from our research group 
suggest that both the N- and C-terminal regions of nsP2 are required for this 
function (unpublished data). In addition to its enzymatic activities, nsP2 of Old 
World alphaviruses is responsible for shutting down host cell RNA and protein 
synthesis and is capable of inhibition of the antiviral interferon response (Frolov 
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et al., 1999; Breakwell et al., 2007; Fros et al., 2013). The nsP2 of SFV, but not 
that of all Old World alphaviruses, has a motif that is similar to the nuclear 
localization signal (NLS). The presence of this motif appears to be important for 
the virus because almost half of synthesized nsP2 is localized to the cell nucleus 
during infection (Rikkonen et al., 1992). Until recently, the nuclear functions of 
nsP2 were not understood. However, it was recently shown that nsP2 within the 
nucleus is capable of initiating the degradation of the catalytic subunit of 
cellular RNA polymerase II and thereby of shutting down cellular transcription. 
Interestingly, the protease activity of nsP2 seems not to be required for this 
activity (Akhrymyk et al 2012). Modification of the putative NLS of the nsP2 of 
SFV results in predominantly cytoplasmic localization of the protein and 
remarkably reduces the cytotoxicity of the virus as well as its ability to co-
unteract the induction of type I interferons (Breakwell et al., 2007; Tamm et al., 
2008; Nikonov et al., 2013). Mutations of this type also reduce the patho-
genicity of SFV infection for mice (Fazakerley et al., 2002). 
nsP3 (482 aa) has been and remains the least well understood alphavirus 
replicase protein. In the majority of alphaviruses, the region encoding the C-
terminal portion of nsP3 contains an in-frame termination codon. Termination at 
this codon results in the synthesis of a shorter P123 polyprotein, while its read-
through, which occurs at a frequency in the range of 10–20%, results in 
expression of full-length P1234 (Strauss and Strauss, 1994). Unlike other nsPs, 
nsP3 lacks any enzymatic activity that can be clearly linked to the viral in-
fection cycle. Nevertheless, it is an essential part of the replication complex and 
is required for synthesis of negative-strand RNA and SG RNA  (Dé et al., 
2003). nsP3 interacts with nsP1 and, as part of the P123 and P1234 poly-
proteins, redirects the localization of replicase complexes from the plasma 
membrane to intracellular membranes. Thus, nsP3 is clearly important for the 
formation of CPVs (Salonen et al., 2003). Two globular domains exist within 
the conserved N-terminal two-thirds of nsP3: a macro domain and a zinc-
binding domain (Shin et al., 2012). In contrast, the C-terminal region of nsP3 is 
not conserved and is apparently intrinsically disorganized. It is very likely used 
as a “hook” that is essential for interaction with various host proteins. The roles 
of these interactions have been revealed only for a few nsP3-binding proteins 
(Panas et al., 2012). Because the C-terminal portion of nsP3 is likely designed 
to acquire and/or lose various motifs that are required for interactions with host 
proteins, this region is also very tolerant of mutations (LaStarza et al., 1994). 
Similarly, the C-terminal region is tolerant of the insertion of large tags, 
including fluorescent proteins and luciferases (Attarzadeh-Yazdi et al., 2009). 
nsP4 (614 aa) is an RdRp and therefore essential for viral replication 
(Rubach et al., 2009). nsP4 also has terminal adenyl transferase activity, which 
is needed for the synthesis of poly(A) tails on positive-strand RNAs (Hardy and 
Rice, 2005; Tomar et al., 2006). The N-terminal region of nsP4 has no 
homology with known proteins and is likely involved in interactions with other 
nsPs. It has been observed that the levels of nsP4 in infected cells are much 
lower than those of other ns-proteins. One reason for this is that on its own nsP4 
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is very unstable; unless it is located in complexes with other ns-proteins, it is 
rapidly degraded (de Groot et al., 1991). A second reason is that the full-length 
P1234 of the majority of alphaviruses is 5- to 10-fold less abundant than P123, 
which is produced as result of termination at the in-frame termination codon 
(Strauss and Strauss, 1994). The exact reasons for the observed down-regulation 
of nsP4 levels are not known; however, the downregulation of expression of 
RdRp is clearly not unique to alphaviruses because a similar phenomenon is 
frequently observed in different viruses with RNA genomes.   
Synthesis of structural protein; NC and virion assembly. The translation 
of the alphavirus structural polyprotein C-p62(E3E2)-6K/(TF)-E1 on the SG 
RNA template takes place in the vicinity of CPVs. In SINV and SFV, the region 
of SG-RNA that encodes the amino terminus of the C-protein is essential to 
boost expression of the structural polyprotein and is therefore termed a 
‘translational enhancer’ (Frolov and Schlesinger, 1994). This element is active 
only in infected cells and is not universally present in all alphaviruses; for 
example, VEEV and apparently CHIKV lack this element. Like the ns-poly-
protein, the structural polyprotein is also processed rapidly. During this pro-
cessing, C-protein, which possesses a serine protease domain at its carboxy-
terminus, cleaves itself from the rest of the polyprotein. This cleavage uncovers 
a signal at the N-terminal region of the remaining p62-6K-E1 polyprotein that 
targets it to the endoplasmic reticulum (ER) membrane, where translation 
continues. The remaining cleavages of the structural polyprotein are catalyzed 
by cellular enzymes. In ER membranes, the peptide bonds between p62 (the 
precursor of E3 and E2), 6K and E1 are processed. p62 and E1 form hetero-
dimers that are transported to the plasma membrane. During this transport, p62 
is cleaved in the trans-Golgi compartment to form the E2 and E3 proteins 
(Zhang et al., 2003). Transport in the form of p62:E1 complexes rather than in 
the form of mature E2:E1 complex is essential to prevent premature con-
formational change of E1 into the fusogenic form during its transport through 
cellular compartments with low pH.  A ribosomal frameshift signal has been 
found in the sequence that encodes the 6K protein. In cases in which the frame-
shift occurs (the frequency of this event is approximately 10%), translation of 
the structural polyprotein results in the synthesis of TF protein (Figure 1). TF 
protein is associated with assembled virions (Firth et al., 2011), and its presence 
is essential for alphavirus-induced in vivo pathogenesis (Snyder et al., 2013). 
The assembly of alphavirus virions begins with the formation of NC. This is 
initiated by the interaction of C-protein with genomic RNA. The encapsidation 
signal, which is essential for this interaction, is localized to the ns-region of 
RNA genome; thus, only genomic RNAs but not SG RNAs are packed into 
NCs. It has been shown that C-protein assembles with the encapsidation signal 
area and that icosahedral NCs are formed. The viral glycoprotein complexes 
formed as described above are transported to the cell surface, where the spike-
structures are inserted into the plasma membrane. The key to the final formation 
and budding of mature virions is the interaction between the NC and the E1:E2 
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dimer (Suomalainen et al., 1992; Jose et al., 2009). The released virions are 
capable of infecting other cells.  
Infection of the central nervous system (CNS). The names of New World 
alphaviruses reflect their ability to infect the CNS. However, some Old World 
alphaviruses also possess this property. During a recent outbreak, several lethal 
cases of CHIKV infection were associated with infection of the CNS (Couderc 
et al., 2008). Although several commonly used laboratory strains of SINV and 
SFV are pathogenic for mice and rats while other strains are not, all SFV strains 
can cross the blood-brain barrier. Therefore, these viruses have been used as 
model systems in attempts to understand the mechanisms of viral neuropatho-
genesis. It has been found that infection of the CNS by alphaviruses depends 
not only on the virus strain but also on the age of the animal (or, in case of in 
vitro systems, on the developemental stage of cultivated neurons) (Griffin, 
2005). All strains of SFV and SINV can cause lethal disease in neonatal and 
suckling mice (Atkins et al., 1999; Fazakerley et al., 2002; Griffin, 2005), while 
only pathogenic strains can kill adult mice. The route of infection is another 
important factor. Infection with the SFV4 strain is pernicious to 60–70% of 
Balb/c mice when the virus is administered intraperitoneally (i.p.); when given 
intranasally (i.n.), the same virus strain killed all mice by causing lethal 
encephalomyelitis at 5–7 days post-infection. Avirulent strains of SFV, such as 
the A7(74) strain, do not cause encephalitis in adult mice; instead, they induce 
nonlethal demylinating disease that generally lasts for up to a month after 
infection (Glasgow et al., 1991, 1994; Santagati et al., 1995, 1998; Tarbatt et al., 
1997; Atkins et al., 1999; Fazakerley, 2004). The genetic basis for the differing 
neurovirulence of SFV strains is not completely understood. Several older 
reports suffered from problems with viral icDNA clones, and these topics are 
currently under re-investigation in our laboratory and in other laboratories.  
The mechanism of immune clearance of non-lethal alphaviruses from the 
CNS has been mostly studied using SINV. Such studies have revealed that viral 
clearance occurs in three phases. During the first phase (days 3–7 after exposure 
to the virus), the infectious virus is cleared. This is followed by the clearance of 
the majority of viral RNA (days 8–60) and finally by a phase in which a very 
low level of viral RNA is maintained (Metcalf and Griffin, 2011). The immune 
mechanisms responsible for viral clearance are generally non-cytolytic; both 
cytokines and antibodies are required for the clearance to occur (Metcalf et al., 
2013).  
 
Alphavirus-based vector systems 
Any alphavirus can be used to develop a vector system. However, the alpha-
viruses most frequently used as vectors, are those that are also the most studied. 
All alphavirus-based vectors are constructed using infectious cDNA (icDNA) 
clones of the corresponding viruses. The first SFV-based vector was constructed 
in 1991 when an infectious cDNA clone of SFV was developed (Liljeström et 
al., 1991).  
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Several methods can be used to classify alphavirus-based vectors. In this 
work, the vectors are divided into two major groups, full-length vectors and 
replicon vectors, based on the presence or absence of the structural region of the 
viral genome. Both types of vectors can exist as RNA-launched systems and as 
DNA/RNA-layered vectors (Figure 2). Common elements of all these vector 
constructs are cDNA of sequences corresponding to the ns-region, 3’ and 5’ 
UTR elements and natural or duplicated SG promoters of the virus genome. 
Unlike replicon vectors, full-length vectors also contain sequences essential for 
virion formation. The major difference between RNA-launched and DNA/ 
RNA-layered vectors is the mode of production of infectious RNA molecules. 
In case of RNA-launched vectors these molecules are produced in a test tube 
using in vitro transcription; accordingly the cDNA of the vector is under control 
of a bacteriophage (SP6 or T7) RNA polymerase promoter. In the case of 
DNA/RNA-layered vectors, transcription is carried out in the nucleus of a cell 
that has been directly transfected with plasmid containing the cDNA of the 
vector; in these vectors, the cDNA sequences are placed under the control of a 
promoter for eukaryotic RNA polymerase II (the immediate early promoter of 
human cytomegalovirus (CMV) is the most frequently used). A more detailed 
description of each type of vector is given below.  
Full-length RNA-launched vectors are also called genomic or replication-
competent vectors (Figure 2A). In their RNA form, these vectors contain the 
complete (or nearly complete) viral genome; in addition, they typically contain 
inserted gene(s) of interest and/or regulatory elements. The most important 
property of these vectors is that they can not only perform RNA replication, a 
property that is shared with replicon vectors, but also express structural proteins 
and produce infectious virions. Such vectors are essentially modified alpha-
viruses that can infect cells and spread in cell culture (or in organism); with the 
exception of their ability to express some foreign genes, they have the same 
features as wt alphaviruses. The use of full-length RNA-launched vectors offers 
several advantages. First, these vectors are easy to produce in large amounts in 
cell culture (no packaging systems or packaging cell lines are required). Second, 
these vectors are almost always characterized by high-level but short-term 
expression of a gene of interest, such as a sequence coding for a tumor antigen, 
and by the ability to induce apoptosis of infected cells. These properties make 
them promising as tools in anti-cancer therapy (Barry et al., 2010; Quetglas et 
al., 2010). One vector of this type that was constructed on the basis of SINV has 
been experimentally shown to have the ability to destroy cancer cells in vivo 
upon being directly injected into the tumor (Tseng et al., 2009). However, 
because alphaviruses can infect a variety of cell types, full-length vectors also 
tend to kill other types of cells and, importantly, can spread infection from the 
injection site to other tissues. Thus, their use could be beneficial (for example, 
in targeting of tumor metastasis) but also could be dangerous to the organism. 
Full-length vectors must therefore be modified either to replicate only in 
targeted cells or, at the very least, modified so that they are restricted from 
infecting cells, tissues and organs (such as cells of the CNS) in which they 
19 
otherwise might cause serious damage resulting in disease. Interestingly, SINV 
has been reported to possess natural tropism to tumor cells (Gardner et al., 
2000; Tseng et al., 2002). However, most alphaviruses seem to lack this useful 
property; therefore, the vectors derived from these viruses must be controlled by 





Figure 2. Schematic representation of the main types of alphavirus-based vectors. The 
constructs shown in panels A-C represent in vitro transcripts prepared using test-tube 
reactions; they are identical to the RNA molecules present in transfected/infected cells. 
Elements of the vector construct that are present only in the DNA plasmid are not 
shown. 
A.  Full-length RNA-launched vector with duplicated SG promoter and inserted gene of 
interest (GOI). Other commonly used sites for insertion of foreign genetic infor-
mation are indicated by open arrows. 
B.  RNA-launched replicon vector. Commonly, the gene of interest is inserted under the 
control of the native SG promoter; however, the vector may also contain duplicated 
SG promoters and/or inserted IRES elements. 
C.  Basic helper vector for RNA-launched replicon vector. 
D.  Full-length DNA/RNA layered vector in the form of an infectious plasmid. CMV – 
immediately early promoter of CMV, ^ – inserted intron (essential for some but not 
all DNA/RNA layered alphavirus vectors), Rz – negative strand ribozyme of 
hepatitis D virus. 
E.  DNA/RNA layered replicon vector in the form of a plasmid construct. 
F.  Helper vector for DNA/RNA layered replicon vector in the form of a plasmid 
construct. Integration of similar DNA into the genome of cell allows construction of 
packaging cell lines usable for both types (RNA-launched or DNA/RNA layered) of 
replicon vectors. 
All of the vectors shown in the figure can be further engineered to contain mutations, 




In some cases, alphavirus-based vectors that rely solely on the intrinsic pro-
perties of the parental virus (such as cell killing or activation of the interferon 
response) and require minimal, if any, modification are designed. However, in 
most cases, it is necessary to design vectors that also express foreign sequences 
and/or contain other artificially generated elements such as miRNA-encoding 
sequences or target sites for cellular miRNAs. There are several different ways 
to insert and express foreign genes using full-length alphavirus-based vectors. 
The main hurdles are keeping the vector genetically stable and achieving the 
desired (usually high) level of foreign protein expression. One obvious way of 
achieving these goals is to express the gene of interest together with the virus’ 
own ns- or structural proteins. Examples of the former are constructs in which 
fluorescent proteins, luciferases or other marker proteins have been inserted into 
the carboxy-terminal region of nsP3. This approach provides the opportunity to 
visualize viral replication in infected cells. In one such vector, a region 
encoding enhanced green fluorescent protein (EGFP) was placed between the 
coding regions for nsP3 and nsP4 and flanked by nsP2 protease recognition 
sites, which were required to achieve release of EGFP from the ns-polyprotein 
(Tamberg et al., 2007; Fragkoudis et al., 2009). Sequences coding for fluore-
scent proteins have also been inserted in different locations within the nsP3-
coding region in SINV, resulting in viruses that express nsP3-EGFP (Frolova et 
al., 2006) or nsP2-EGFP (Atasheva et al., 2007) fusion proteins. These viruses 
were used to visualize the synthesis and location of nsP2 and nsP3 and to 
identify host proteins that interact with these viral proteins and/or with the viral 
replicase. Because the expression of ns-proteins by alphaviruses is short-term, 
usually ending by 6–8 hours post-infection, and occurs at a relatively low level, 
such constructs are not suitable for applications in which a high level of 
expression of the gene of interest is essential. 
The expression of alphavirus structural proteins occurs at a much higher 
level (100-fold or more) than expression of ns-proteins and, importantly, 
continues during the late stages of infection. This has made the structural ORF a 
promising region for the insertion of foreign sequences. The first such suc-
cessful strategy developed was the insertion of an EGFP sequence between the 
C-protein and E3 regions (Thomas et al., 2003) of the SINV vector; the 
resulting virus was reported to show a high level of marker protein expression 
and superb genetic stability. However, this was not the case for similar SFV-
based vector: the corresponding virus was clearly growth-attenuated and rela-
tively unstable (Fragkoudis et al., 2009; our unpublished data). More recently, 
strategies to express marker proteins fused to the glycoproteins of alphaviruses 
have also been described. 
An alternative option is to express the gene of interest independently of viral 
proteins; two approaches can be used. In the first approach, the extra protein can 
be expressed using an inserted internal ribosome entry site (IRES). For un-
known reasons, this approach did not work in the context of full-length SFV 
vectors (Rausalu et al., 2009), although it did work well in the context of SFV 
replicon vectors (Kiiver et al., 2008). Nevertheless, the successful construction 
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and use of full-length constructs obtained using the IRES insertion strategy have 
been described (Volkova et al., 2008; Guerbois et al., 2013). However, by far 
the easiest (and hence most commonly used) way to create an independent 
expression unit in an alphavirus vector is duplication of the SG promoter. For 
this, two factors are important. The first is the length of the sequence re-
presenting the duplicated SG promoter. The use of SG promoters that are too 
long can generate problems with vector stability; hence, the promoters should 
be as short as possible and as long as required. In most alphaviruses, the 
minimal active SG promoter has a length of 24 bases (spanning from position  
-19 to position +5; coordinates are given with respect to the start site of SG 
RNA) (Levis et al., 1990) and possesses activity equal to approximately one-
fifth that of the native full-length SG promoter. SFV, however, seems to be an 
exception in that SG promoters nearly twice as long (for example, from position 
-37 to position +17) are required for effectiveness (Rausalu et al., 2009). 
Second, the location of the duplicated SG promoter element (and thus also that 
of the foreign gene) in the vector genome is also important. Again, there are 
differences between different alphaviruses. It has been shown that the best 
region in which to place such an insertion in full-length SFV vectors is the 
region immediately downstream of the structural genes (Rausalu et al., 2009). 
In contrast, for CHIKV and SINV vectors, insertion between the ns- and 
structural regions is preferred (Pierro et al., 2003; Tsetsarkin et al., 2006). 
Again, the reasons for these discrepancies are not understood. 
Two factors set a limit how many SG promoters, IRES elements and foreign 
genes can be inserted into the genome of a full-length alphavirus vector. First, 
each insertion reduces and/or slows down replication of the recombinant 
genome either by interfering with natural gene expression (promoter com-
petition can be observed in cases in which duplicate SG promoters are used) or 
simply by increasing the size of the genome, which then takes a longer time to 
replicate. Second, because the icosahedral NC has a fixed volume, there is a 
limit to the size of the RNA genome that can be incorporated into the NC. 
Although mutations that change the structure of the NC of SINV and increase 
its volume have been described (Ferreira et al., 2003), in general only 2000 or 
slightly more extra nucleotides can be incorporated into full-length alphavirus 
vectors. This number of nucleotides corresponds to a relatively short gene of 
interest and thus represents a serious limitation. As the limit of the gene length 
is approached, the genetic instability of the recombinant full-length vector 
increases rapidly because such vectors have serious growth disadvantages 
compared to wt viruses or aberrant viruses that have lost most of the inserted 
sequences. Accordingly, the large genomes will be rapidly outcompeted during 
vector preparation and propagation. The elimination of the original vector with 
the inserted sequence from the population can be slowed down somewhat by 
selecting appropriate conditions for passaging (in general, the lower the 
multiplicity of infection (MOI) is, the more rapidly inserts are lost) but cannot 
be completely prevented, making the use of such constructs for medical 
purposes highly problematic. 
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RNA-launched replicon vectors (Figure 2B) are basically truncated 
versions of the alphaviral genome in which the structural region has been 
replaced by foreign gene(s) that are typically expressed using the native 26S 
promoter; however, replicon vectors with duplicated SG promoters and/or IRES 
elements have also been developed (Kiiver et al., 2008). Unlike full-length 
vectors, replicon vectors represent a single-cycle expression system. Cells 
transfected with such vector RNAs become infected and, if the vector is based 
on an Old World wt alphavirus, undergo apoptosis. Apoptosis is triggered both 
by high-level replication of the replicon RNA and by the cytotoxic properties of 
wt nsP2; it may be further enhanced (or, in some cases, slowed down) by the 
properties of the expressed protein of interest. In general, cells transfected with 
replicon vectors tend to survive slightly longer than cells transfected or infected 
with the corresponding full-length vectors. The reason for this is the lack of ER 
stress caused by the expression of alphavirus glycoproteins (Barry et al., 2010). 
In contrast, replicon vectors based on New World alphaviruses have only mode-
rate or low cytotoxicity. This difference is due to the fact that the main cyto-
toxic protein of New World alphaviruses is not nsP2 but C-protein (Gar-
mashova et al., 2007a, 2007b), which is not produced from the replicon RNA. 
In vitro-transcribed replicon vector RNAs can be used directly for trans-
fection of the cells of interest. However, this is often impractical due to the 
limited number of cells that can be transfected using transfection reagents or 
physical methods (electroporation). Furthermore, many types of cells can be 
infected by alphaviruses but cannot be efficiently transfected with large RNA 
molecules. To overcome these issues, packing systems for alphavirus replicon 
vectors have been developed. The most straightforward approach is the use of a 
so-called helper vector. Helper RNA is capable of replication in the presence of 
the replicon RNA and, unlike the latter, triggers the expression of structural 
proteins. The basic design of helper vectors is simple. They also consist of a 
truncated alphavirus genome that, in this case, lacks most of the ns-region 
(including the packing signal) but possesses the cis-active sequences needed for 
replication and transcription (5’- and 3’- UTRs, 26S promoter) and the region 
encoding the viral structural proteins. Co-transfection of cells with replicon 
RNA and helper RNA leads to the production of virus-replicon particles (VRP). 
These resemble infectious alphavirus virions but instead of a full-length 
genome, contain packed replicon RNA lacking structural genes. Such VRPs are 
“suicide particles” because they are capable of only one round of infection.  
The primary safety concern associated with the use of VRPs is the pos-
sibility that replicon and helper RNAs will recombine, leading to the formation 
of replication-competent full-length viral genomes. Several approaches have 
been developed to minimize the likelihood of such events. One of these is the 
use of a split helper system. In this system, the regions encoding C-protein and 
glycoproteins were separated in two independent helper RNAs that should then 
be co-electroporated with replicon RNA to obtain VRPs (Smerdou and Lilje-
ström, 1999). A recent study showed that the 26S promoter is not strictly 
required for the production of functional structural proteins from helper RNA 
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(Kamrud et al., 2010b). This permitted the development of promoterless 
helpers, further increasing the safety of the replicon systems. Finally, safe-
guards that render the potential full-length genomes non-viable (or strongly 
attenuated) in cells infected with VRP stocks can be inserted into helper vectors 
(Kamrud et al., 2010a). 
The greatest advantage of standard alphavirus replicon vectors is their ability 
to express high levels of foreign protein. It has been shown that SFV-based 
replicons can express as much as 100 µg β-galactosidase per million infected 
cells (Liljeström and Garoff, 1991). Experiments with VEEV replicons 
expressing Lassa virus N-protein showed that the foreign protein constituted 
approximately 20% of total cellular protein (Pushko et al., 1997). For SFV- or 
SINV-based replicon vectors, the expression of foreign proteins can be further 
boosted by the use of translational enhancers: in such vectors, sequence en-
coding the N-terminal portion of C-protein is fused to the 5’ end of the 
sequence encoding the protein of interest (Sjöberg et al., 1994). This approach 
was used to boost the vector-induced anti-tumoral response caused by 
expression of high levels of IL-12. When high doses of a vector expressing IL-
12 fused to the capsid enhancer were used in mice model, complete tumor 
regression was observed in approximately 80% of cases; even at lower doses, 
vectors with enhancer were more efficient than standard vectors. That study 
also demonstrated that alphavirus-based vectors can be used as anti-cancer 
agents (Rodriguez-Madoz et al., 2005).  
As indicated above, alphavirus-based vectors can express more than one 
gene of interest simultaneously. This property can be used for more efficient 
targeting of the same disease or to simultaneously achieve other goals. For the 
first option, additional genes of interest are included in the vector using an extra 
copy or copies of the SG promoter. Although this approach guarantees simulta-
neous expression of multiple proteins of interest, the expression levels of diffe-
rent proteins are typically not identical even if their expression is mediated by 
SG promoters of the same sequence and length. A vector of this type expressing 
the three CMV proteins pp65, IE1 and gB was constructed and used to vacci-
nate mice against CMV infection. Vaccination with the vector resulted in high 
numbers of antigen-specific T-cells and high titers of neutralizing antibodies 
against CMV (Reap et al., 2007a, 2007b). Thus, such an approach is possible, 
though not necessarily beneficial. A simple and possibly more efficient alter-
native would be to vaccinate using a combination of alphavirus-based vectors 
each of which has been engineered to express one antigen. It is certainly easier 
to manipulate the expression levels of different antigens by changing the 
composition of the mixture than by attempting to manipulate their expression 
levels from a more complex vector. An example of a study in which multiple 
inserted sequences had different goals utilized an SINV replicon vector engi-
neered to express luciferase using an SG promoter as well as a herpes simplex 
virus (HSV) thymidine kinase (TK) fused to nsP3. In this case, the generated 
TK activity offered a means of increasing the safety of the vector because its 
replication and spread could be controlled by the use of the anti-herpesvirus 
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compound ganciclovir (Tseng et al., 2009). Regardless of the goal, it must also 
be kept in mind that although alphavirus replicon vectors can accommodate 
rather large insertions of foreign sequences (up to 6–8 kb), the use of multiple 
SG promoters and multiple genes of interest can easily reach this limit. Finally 
because all duplications represent potential recombination points inside the 
vector sequence, the use of duplications may result in enhanced recombination 
and deletion of one or several genes of interest during the preparation of VRP 
stocks. 
DNA/RNA layered alphavirus-based vectors. The first SINV-based DNA/ 
RNA layered replicon vector was constructed in 1996; a few years later, similar 
SFV vectors were described (Dubensky et al., 1996; Berglund et al., 1998). 
DNA/RNA layered vectors differ from RNA-launched vectors in the design of 
the plasmid-based part of the vector construct (Figure 2D, 2E, 2F); the vectors 
themselves (in the RNA form) can be identical. Plasmid constructs of DNA/ 
RNA layered vectors must contain eukaryotic transcription elements, including 
a promoter for RNA polymerase II (the CMV immediately early promoter is 
often used, but other promoters with fixed transcription start sites can also be 
used) upstream of the vector’s cDNA and a eukaryotic termination element 
(poly(A) signal) downstream of it (Atkins et al., 2008). DNA/RNA layered 
vectors were initially created to avoid expensive RNA production and circum-
vent the problems associated with the instability of large naked RNA molecules 
in vivo. It should also be noted that there are more (and usually more efficient) 
available transfection methods for the delivery of DNA plasmids than for the 
delivery of large RNA transcripts. DNA vectors can also be integrated into the 
host cell genome, while this is completely impossible with RNA constructs. 
Finally, the use of DNA permits some types of regulation (the use of promoters 
with different strengths, the use of inducible promoters) that cannot be used in 
RNA-launched systems. DNA/RNA layered constructs can also be engineered 
to contain introns that help stabilize the vector plasmids and improve viral RNA 
synthesis and export from the nucleus to cytoplasm. DNA/RNA layered vectors 
have the same advantages as other alphavirus-based vectors: low biohazard, 
ability of the vector to induce a high-level and high-quality immune response 
against expressed antigens, and the ability to infect and destroy specifically 
targeted cells such as cancer cells due either to the cytotoxic properties of the 
vector or to activation of an anti-cancer immune response.   
Alphavirus-based long-term expression systems. Short-term expression of 
the genes of interest represents an intrinsic limitation of standard alphavirus-
based vectors. Therefore, attempts have been made to construct systems that can 
be used for long-term or even permanent expression of proteins of interest. 
Although full-length alphaviruses exert their cytotoxic effects through 
several different mechanisms, vectors derived from these viruses as well as 
natural alphaviruses can be adapted to non-cytotoxic growth in a variety of 
mammalian cells (Atasheva et al., 2010). Furthermore, alphaviruses and vectors 
derived from them are naturally able to cause persistent infection of insect cells. 
Unfortunately, these infections are characterized by low-level production of 
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virus and viral products and are therefore hardly suitable for biotechnological 
applications. For these reasons, most researchers’ attention has been dedicated 
to the development of alphavirus replicons that can be used to create stably 
expressing, established cell lines. One approach to this problem is represented 
by the example of a stably transfected cell line in which a DNA/RNA layered 
vector of SINV is integrated into the cellular genome; in this system, activation 
of the replicon and expression of the protein of interest was induced by a 
change in temperature (Boorsma et al., 2003). However, once induced, the 
expression may not be permanent because most temperature-sensitive (ts) 
mutants of alphaviruses do not have non-cytotoxic phenotypes. Therefore, truly 
non-cytotoxic alphavirus replicons were developed. Because New World 
alphavirus-based replicons lack structural proteins, which are the major deter-
minants of cytotoxicity in these viruses, minimal effort was needed to develop 
corresponding non-cytotoxic vectors (Petrakova et al., 2005). A single mutation 
in nsP2 of SINV was found to be sufficient to render the corresponding replicon 
vectors capable of permanent replication (Frolov et al., 1999). With SFV 
replicons, however, the situation proved to be somewhat more complicated. 
Mutations similar to those used in SINV vectors reduced but did not block the 
cytotoxicity of SFV replicons (Lundstrom et al., 2001; Tamm et al., 2008). It 
was later found that two different mutations in nsP2 are needed to attenuate the 
SFV replicon to a level that allows permanent growth in cell lines (Casales et 
al., 2008). This requirement may be general for other alphaviruses similar to 
SFV because two recent studies dedicated to the analysis of the cytotoxicity of 
CHIKV showed that a similar combination of mutations is required to suppress 
the cytotoxicity of the CHIKV replicon (Pohjala et al., 2011; Fros et al., 2013). 
The cell lines generated using non-cytotoxic alphavirus replicons have found 
various uses ranging from the screening of potential antiviral compounds 
(Pohjala et al., 2011) to the production of high levels of human therapeutic 
proteins (Casales et al., 2010). 
 
 
Potential medical applications of alphavirus-based vectors 
The main potential applications of alphavirus-based vectors in medicine lie in 
the areas of vaccine development and anti-cancer therapies (often the latter also 
includes elements of anti-cancer vaccination). 
Alphavirus-based vectors as components of vaccine candidates. Alpha-
virus-based vectors can represent components of genetic or recombinant 
vaccine candidates and, subsequently, vaccines. One of the primary arguments 
in favor of their use in vaccines is that commonly used alphavirus vectors are 
not pathogenic to humans. Furthermore, some alphaviruses, such as SFV, which 
is being used for vaccine development, are not associated with known human 
diseases. This, however, also creates a specific problem in that there are no 
existing human vaccines against any alphaviruses; hence, the potential effects 
(especially the long-term effects and potential adverse side effects) of the use of 
such vaccines are simply not known. In this regard, alphaviruses have a 
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disadvantage as vaccine components compared with viruses such as yellow 
fever virus and vaccinia virus, which have long-documented histories of use as 
vaccines.  
There are a number of obvious advantages associated with the use of 
alphavirus-based vectors as components of vaccines. They include the broad 
host range of the viruses and their ability to infect different types of cells, 
including neuronal and primary cells, their natural tropism to dendritic cells 
(Nishimoto et al., 2007), the simplicity of production of high-titer virus stocks 
and the possibility of using VRPs and/or DNA/RNA layered vectors as extre-
mely safe vaccines. Furthermore, because alphaviruses have RNA genomes and 
replicate in the cytoplasm, there is no risk of integration of viral genetic 
material into the host cell genome. Alphavirus-based vectors that carry and 
express many different foreign genes can be constructed (Reap et al., 2007b); 
alternatively, different constructs can be mixed to obtain multivalent vaccines 
(White et al., 2013). Like any virus-based system, alphavirus vectors cannot 
serve as a universal vaccine platform. Some properties of alphaviruses confer 
benefits for certain applications, while restrictions are implied by others. Thus, 
although the small genomes of alphaviruses make genetic modification 
relatively simple, they also preclude the use of large inserts containing foreign 
genetic information. Furthermore, high-level expression of genes of interest is 
balanced by the short-term nature of the expression. Alphavirus vectors also 
activate innate immune responses, both humoral and cellular, ensuring a high-
quality immune response against the target; however, anti-vector immunity is 
also efficiently generated (Lundstrom et al., 2003; Atkins et al., 2008). 
Many alphavirus-based vectors have passed preclinical evaluation, and some 
have been tested at early clinical stages. So far, these vaccine candidates have 
been based on replicon vectors, which have been used because of their greater 
safety. VEEV-based vectors are more frequently used than others because in 
earlier studies it was shown that replicon vaccines derived from VEEV were 
significantly more immunogenic then replicon vaccines derived from SINV 
(Perri et al., 2003). However, other alphaviruses such as SFV may also have 
their benefits; SFV vectors have been shown to induce superior T-cell responses 
(Knudsen et al., 2012), and they can also be developed into more sophisticated 
hybrid vectors that induce the production of superior levels of neutralizing 
antibodies (Rose et al., 2008). The examples provided below describe several 
vaccine candidates that are based on VEEV replicon vectors:   
– The company AlphaVax carried out several studies with the aim of 
developing vaccine candidates against CMV (with the aim to prevent CMV-
induced congenital disease). In one study, VEEV vectors containing single-, 
double-, and triple SG promoters were used to express the individual CMV 
proteins gB, pp65 and IE1 or a pp65/IE1 fusion protein. In infected cell 
cultures, CMV proteins were expressed at high levels, and induction of 
robust antibody responses to gB and cellular immune responses to pp65 and 
IE1 was observed in immunized mice (Reap et al., 2007a). This study was 
followed by a phase 1 clinical trial in which the vaccine candidate was 
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tested in seronegative adult volunteers. In this trial, two-component replicon 
vectors expressing gB or a pp65/IE1 fusion protein were used. The vectors 
were found to be safe and to induce high levels of neutralizing antibodies as 
well as polyfunctional antigen-specific CD4+ and CD8+ T-cell responses 
(Bernstein et al., 2009). 
– In a study carried out by Global Vaccines Inc., VEEV replicons were used 
in an attempt to develop a tetravalent vaccine against dengue virus (DENV). 
The tetravalent vaccine represented a mixture of VRPs, each of which 
encoded a specific glycoprotein (in the final setup, the E85 configuration of 
the glycoprotein) of one DENV serotype. This vaccine produced a balanced 
immune response and fully protected macaques against all four serotypes of 
DENV. Importantly, no evidence of interference between the various 
components of the vaccine was observed, and the anti-VEEV immunity was 
found not to hamper the booster immunization (White et al., 2013).  
– Last but not least, AlphaVax tested an alphavirus-based anti-influenza 
vaccine candidate. The VRPs expressing the NA and HA proteins of 
influenza virus were found to induce high-titer antibody responses in all of 
the experimental animals used (mice, rabbits and rhesus macaques), and 
robust cellular immune responses were observed in mice and rhesus 
macaques. Toxicology studies performed in rabbits revealed no adverse 
effects of the vaccine candidate (Hubby et al., 2007). 
 
Use of alphavirus-based vectors in anti-cancer vaccination and cancer 
treatment. Over the years, alphavirus vectors have been used in numerous 
attempts to treat various types of cancers including melanoma, prostate cancer, 
breast cancer and cervical carcinoma. Similarly, many different approaches 
have been tested, including the use of DNA vaccines, VRPs or even cells 
transduced with VRPs. Constructed alphavirus vectors have been engineered to 
express proteins that boost the immune response, tumor-associated antigens 
(TAA), members of various kinase receptor families, and other functional 
proteins. Although to date the majority of these studies have been preclinical 
and have enjoyed varying degrees of success, they have provided important 
knowledge on how to improve and use alphavirus-based anti-cancer vectors. 
These studies also revealed for the first time that alphavirus-based DNA 
vaccines can activate the innate immune response. It was also observed that the 
quality of host immune response does not depend only on the amount of 
expressed antigens. Several examples of such studies are provided below. 
– Two studies by a single research group describe vaccination of mice against 
melanoma using DNA/RNA layered SINV replicon vectors. In the first 
study, vectors expressing tyrosinase-related protein 1 (TRP-1) were used. It 
was found that the alphavirus-based vector was capable of breaking the 
host’s immune tolerance to the tumor. Furthermore, this effect was not 
observed in mice lacking RNaseL, indicating that it was dependent on the 
synthesis of double-stranded RNAs (Leitner et al., 2003). In the second 
study, the same vector was used in combination with a vector expressing 
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the anti-apoptotic Bcl-X(L) protein. It was observed that the presence of the 
Bcl-X(L) expression vector increased the lifespan of transfected cells, 
boosted the production of tumor antigen and increased the production of 
antibodies against this antigen. However, animals vaccinated with combi-
nation of these two vectors nevertheless displayed decreased protection 
against aggressive tumors. Thus, a correlation between the ability of the 
alphavirus-based vector to induce apoptosis of transfected cells and in vivo 
protection against challenge with melanoma was observed. These data 
indicate that alphavirus-induced apoptosis is essential for protective anti-
cancer immunity (Leitner et al., 2004).  
– Another strategy is to use antigen-specific dendritic cells (DC) as vaccine 
against established tumors. In one such study, a tumor overexpressing Neu 
oncoprotein (Neu is overexpressed in approximate a quarter of human 
breast cancers) was targeted. First, murine DCs were infected with VRPs of 
VEEV expressing truncated Neu oncoprotein. Delivery of these DCs to wt 
mice with established tumors resulted in high levels of Neu-specific CD8(+) 
T cell and anti-Neu IgG responses; furthermore, these responses were able 
to induce the regression of the tumors and enhance the survival of the mice 
(Moran et al., 2007). 
 
Only a few alphavirus-based anti-cancer vaccines have been tested in phase I/II 
clinical trials. The first such study was conducted by AlphaVax with the aim to 
evaluate the induction of an immune response against colon cancer using VRPs 
of the VEEV expressing carcinoembrionic antigen (CEA). Like the pre-clinical 
studies, this trial showed that the vaccine candidate was safe and that it was 
capable of breaking immune tolerance to the self-antigen. In another study, it 
was shown that anti-vector neutralizing antibodies do not necessarily block the 
therapeutic use of VRPs. A phase I trial conducted using VRPs of VEEV 
expressing CEA revealed that repeated administration of VRPs was also 
capable of overcoming the negative effect of elevated levels of suppressive cell 
populations (Treg). Clinically relevant CEA-specific antibody and T-cell 
responses were observed in treated cancer patients. Most importantly, the CEA-
specific antibodies mediated antibody-dependent cellular cytotoxicity against 
tumor cells from human colorectal cancer metastases, and patients with CEA-
specific T-cell responses exhibited longer overall survival (Morse et al., 2010).  
Another clinical trial, this time targeting melanoma, is expected to begin in 
2014. The vaccine to be tested is again based on VRPs of VEEV; in this case, 
the vector encodes the melanoma differentiation antigen TRP-2. It was pre-
viously shown that immunological tolerance to the tumors can be broken in 
mice immunized with VRPs of VEEV or SINV DNA/RNA layered vectors 
expressing the related TRP-1 antigen (Leitner et al., 2003; Goldberg et al., 
2005). Newer data also show that vectors encoding TRP-2 induce the activation 
of TRP-2-specific humoral (IgG) and effector CD8+ T-cell responses and cause 
accumulation of CD8+ T-cells within tumors (Avogadri et al., 2010).  
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Despite these promising results, it is increasingly clear that it is impossible to 
cure a broad range of tumors by vaccinating only against TAAs. It is frequently 
not known which TAAs are present in specific types of cancer cells; further-
more, cancers contain different cells, some of which can escape the induced 
anti-TAA immune response. Therefore, it is important to develop different 
approaches and frame various strategies. One promising strategy is based on the 
ability of alphaviruses to kill infected cells. The use of this approach depends on 
the ability to specifically target tumor cells with viruses. SINV is known to use 
the laminin receptor (LAMR) to enter mammalian cells (Wang et al., 1992), and 
the expression of this receptor is upregulated in many cancers (accordingly, 
there is an excess of free LAMR not bound to laminin on the surface of cancer 
cells). This results in a natural affinity of SINV for tumor cells, which can likely 
to be enhanced by modifying the vector. Together with the alternative options 
that are described briefly in the next section, this type of modification can be 
used to generate efficient alphavirus-based vectors that not only induce anti-
cancer immune responses but also directly kill cancer cells.  
 
 
Approaches to the control of alphavirus-based vectors 
Virus-based replication-competent vectors tend to be more potent tools for 
foreign protein expression than vectors with impaired replication and/or spread. 
However, they also carry significant biological danger. Therefore, one of the 
central tasks in the development of such vectors is to achieve control over their 
replication and spread. For any virus-based vector, this is no easy task, but it is 
especially challenging for viruses with RNA genomes. Indeed, viruses with 
DNA genomes can be manipulated by the use of tissue-specific regulatory 
elements (promoters, enhancers, etc.) originating from different sources (other 
viruses, hosts). This approach is not possible with RNA viruses because their 
replication and gene expression are not controlled by such sequences. Although 
RNA viruses do display tissue specificity, the reasons for this (aside from the 
presence of receptors) are generally poorly and often not at all understood. 
Furthermore, a lack of proofreading function and a tendency to recombine cause 
instability of recombinant RNA virus-based vectors, which tend to revert, 
pseudorevert and/or compensate for introduced changes. However, because 
RNA-virus-based vectors have undeniable potential in numerous applications 
(see the examples provided above for alphaviruses), numerous approaches to 
control these vectors have been envisioned and tested. Most of the approaches 
that have been used are strictly virus-specific and are therefore not applicable to 
other viruses. The following descriptions give an overview of novel approaches 
that are applicable to many unrelated viruses and viral vectors. 
Regulation of viral vectors using miRNAs. MiRNAs are a class of site-
specific post-transcriptional regulators. They are small, approximately 21–25 nt 
long, non-coding RNA molecules that bind to complementary sequences 
typically located in the 3’ UTR regions of mRNAs (Lee et al., 1993). MiRNAs 
are produced in all cells of the body except those without nuclei. Many 
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miRNAs are tissue-specific. Furthermore, the expression of certain miRNAs is 
up- or downregulated in cancer cells (Chen, 2005). The varying abundance of 
different miRNAs (in extreme cases, the complete absence of some miRNAs) in 
particular cell types provides an opportunity to use the existing miRNA 
repertoire to control the replication and gene expression of viral vectors. In fact, 
this strategy is used by viruses themselves; the best known example is hepatitis 
C virus (HCV), which requires miR-122 as a cofactor for replication (Jangra et 
al., 2010). Alternatively, viruses can be engineered to express miRNAs. Again, 
this is a natural property of many DNA viruses that either encode miRNAs or 
affect the expression of cellular miRNAs (Grey et al., 2008). More recently, it 
has been reported that RNA viruses can also encode miRNA-like molecules 
(Hussain et al., 2012). 
It is challenging to construct viral vectors whose replication is strictly 
dependent on the presence of a particular cellular miRNA (that is, to create 
positive regulation by miRNAs as naturally occurs in the case of HCV). In 
contrast, negative regulation by existing miRNAs is relatively easy to achieve, 
requiring only the insertion of miRNA target sites into the genome and/or 
transcripts of the virus. Negative regulation by existing miRNAs represents an 
approach that is applicable to all types of viruses. For example, it has been 
shown that the introduction of target sites of mir-143 or mir-145 into transcripts 
of the ICP4 gene of an HSV-based vector restricted the vector’s replication to 
human prostate cancer cells, in which the expression of these miRNAs is down-
regulated. In a mouse model, the recombinant HSV reduced the growth of 
human prostate cancers by 80%; importantly, the recombinant virus displayed 
much lower virulence than the non-targeted virus in normal tissues (Lee et al., 
2009).  This strategy, in which miRNAs allow the viral vector to replicate only 
in selected cells, can be designated the “keeping in” approach. The introduction 
of target sites of the neuron-specific miRNAs mir-124 or Let7 into the polio-
virus genome was shown to result in significant reduction of viral neurotoxicity 
in mice (Barnes et al., 2008). This shows that miRNA-based regulation is 
applicable to RNA viruses as well. However, in contrast to the previous case, 
this represents an example of the “keeping out” strategy, in which recombinant 
virus is restricted from replication in certain cell types. It has also been shown 
that miRNAs can be used to improve the safety of viral vectors. The intro-
duction of target sites of common and abundant miRNAs into helper RNAs of 
VEEV replicon vectors resulted in drastic down-regulation of the replication 
and spread of corresponding full-length virus (representing an unwanted 
product of recombination between helper and replicon RNAs) in cell culture as 
well as in vivo (Kamrud et al., 2010b). Basically, the replication of such RNAs 
becomes dependent on artificially added miRNA inhibitors; therefore, such 
genomes can be considered to harbor a conditionally lethal defect.  
Because miRNA inhibitors are typically modified antisense oligonucleotides 
(ASO), the use of these molecules as essential cofactors for conditionally lethal 
viral vectors may seem impractical because of the high cost. However, this is 
not necessarily so. This class of compounds is well-represented in the pipelines 
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of many pharmaceutical companies, mostly as anti-cancer drug candidates. One 
such candidate is the ASO AP12009, an inhibitor of growth factor beta (TGF-β, 
a regulatory molecule that is commonly overexpressed in malignant tumors and 
is associated with cancer progression). AP12009 has reached phase I/II clinical 
trials in high-grade glioma, pancreatic carcinoma and melanoma patients and 
represents a promising candidate drug for the treatment of malignant tumors 
(Schlingensiepen et al., 2006).  Another common target of ASOs is Bcl-2 anti-
apoptotic oncoprotein. Considering how difficult it is to achieve complete 
suppression of cancer growth, one can envision that ASOs targeting genes such 
as TGF-β or Bcl-2 might be co-delivered with ASOs that enable the replication 
of miRNA-controlled virus in the targeted cancer.  
As indicated above, all RNA viruses are genetically flexible. As a con-
sequence, unfavorable changes to the viral genome are rapidly reverted or 
compensated for. As expected, this was found to be the case for miRNA targets 
inserted into RNA genomes (Barnes et al., 2008). The selective pressure toward 
elimination of the insert can, however, be alleviated by the use of miRNA 
inhibitors, which should be used at the stage of preparation of VRP or re-
combinant virus stocks. However, under in vivo conditions, viruses would still 
revert. This is a valid concern, although not necessarily a problem: reversions to 
wt are also common for several live attenuated vaccines. Thus, initial inhibition/ 
restriction of virus replication may be sufficient to block unwanted effects. 
Nevertheless, it is obvious that viral vectors with positive miRNA regulation 
would be more stable than vectors using negative regulation. This is illustrated 
by the recent phase II clinical trial of an inhibitor of liver-specific miR-122 
which, as indicated above, is an essential co-factor in HCV replication. The 
drug candidate miravirsen, a locked nucleic-acid-based modified DNA 
phosphorotrioate ASO, caused long-term reduction in HCV titers, and, im-
portantly, no viral escape mutants were detected (Janssen et al., 2013). Thus, 
even under clinical conditions, a virus controlled by miRNA in a positive 
manner was unable to escape from dependence on a particular miRNA. 
Unfortunately, the artificial construction of vectors with this type of miRNA 
dependence is difficult, and to my knowledge, no example of such a vector has 
been described.     
Defective introns as tools to control the rescue of recombinant viral 
genomes from cDNA-containing constructs. Splicing is a biological process 
that regulates gene expression in eukaryotes by generating mRNAs coding for 
multiple protein isoforms with diverse functions from single pre-mRNA 
transcripts (Goemans et al., 2011; Mendell et al., 2012). Because positive-strand 
RNA viruses of eukaryotes replicate exclusively in the cytoplasm of infected 
cells, they do not encounter the host cell RNA splicing system. As a con-
sequence, by random chance, their genomes contain numerous sequences that 
could be recognized by the cellular RNA splicing machinery as cryptic introns. 
For the use of RNA-launched vectors, this does not represent any problem or 
benefit. However, the presence of cryptic introns could affect the properties of 
DNA/RNA layered vectors because in this case, the synthesis of RNA occurs in 
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the nucleus and mature RNA, acting as the genome of the vector, must be 
transported to the cytoplasm. Compared to the majority of cellular mRNAs, the 
alphavirus genome is relatively large (>11 kb); it is rather unusual for an RNA 
of this size to be copied from a gene containing a single exon. This leads to two 
problems. First, in the absence of true introns, the cellular splicing machinery 
will use the cryptic introns that are always present in alphavirus genomes. This 
will lead to the production of defective RNAs lacking part of the viral genome 
but having most (or all) of the cis-elements required for viral replication. In the 
presence of a full-length virus (or vector) genome, such RNAs can function as 
defective interfering RNAs. Second, because the splicing machinery is 
connected to the systems responsible for transport of mRNA from the nucleus 
to the cytoplasm, the non-spliced large viral RNAs may accumulate in the 
nucleus or be transported to compartments of the cytoplasm that are not optimal 
for translation and the subsequent initiation of replication. Because similar 
considerations are applicable to all positive-strand RNA viruses, it is hardly 
surprising that various research groups have begun to incorporate introns into 
DNA/RNA layered vectors of plant and animal viruses (González et al., 2002; 
Marillonnet et al., 2005). An additional benefit of this strategy is that it also 
helps prevent the cryptic expression of viral genes in E. coli; as described in the 
Results and Discussion section, such cryptic expression may cause instability of 
plasmids containing the cloned cDNA of the virus.  
Intron-insertion technology also offers other possibilities. Specifically, not 
all introns facilitate RNA maturation or are spliced away correctly. It is well 
known that for many pre-mRNAs different schemes of splicing are used; in 
addition, defective introns that result in aberrant splicing of preRNAs are also 
known to occur. The latter, occur during the maturation of β-globin mRNA, 
results in β-thalassemia, a disease caused by reduced synthesis of the hemo-
globin beta subunit. β-thalassemia is a very common illness: approximately 200 
different mutations in the β-globin gene (combined, these affect nearly 20% of 
the human population) are associated with this disease and related disorders 
(Olivieri, 1999). Several of the mutations associated with the disease are located 
in the first or second intron of the β-globin gene, where they create incorrect 
(but efficient) splicing sites and thus cause aberrant splicing of β-globin pre-
mRNA (Figure 3). In such RNAs, introns are not completely removed and the 
reading frame of β-globin is interrupted. In particular, aberrant splicing of the 
second intron of the β-globin gene is caused by two different and independent 
(not occurring together in nature) mutations: the change of a T nucleotide to G 
at position 705 and the change of a C nucleotide to T at position 654. Both of 
these changes create new 5` aberrant donor sites and activate a common 
3`cryptic acceptor site (Figure 3A). Because β-thalassemia is a common 
disease, numerous studies have attempted to develop compounds capable of 
blocking this aberrant splicing and thus restoring synthesis of normal β-globin. 
Some such compounds, called splice-switching oligonucleotides (SSOs), have 
indeed been developed. Briefly, SSOs are ASOs that bind to the mutant splicing 
region and prevent its access by the splicosome and other splicing factors 
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(Figure 3B). This results in a blockade of incorrect splicing and, importantly, 
restoration of the correct splicing pattern (Dominski and Kole, 1993; Bauman et 




Figure 3. Schematic representation of aberrantly spliced intron (second intron 
of human β-globin gene). For simplicity, the intron is shown inserted into the 
coding sequence of the luciferase reporter gene. The beginning and end of the 
intron are indicated by arrows; the positions of cryptic splicing sites created by 
mutations associated with β-thalassemia and the common cryptic splice site 
(CSS) that is activated by these mutations are indicated by open arrows. 
A. Aberrant and correct splicing possibilities of introns with mutations 
associated with β- thalassemia. mRNAs resulting from different aberrant 
splicing pathways contain parts of an intron that has not been removed and 
therefore encode defective proteins. 
B. Principle of action of splice-switch oligonucleotides (SSO). SSOs bind to 
mutated sequence and block aberrant splicing; therefore, the intron is 






The effects caused by aberrantly spliced introns are also reproduced in the 
heterologous context. If an incorrectly spliced intron is inserted into a coding 
region of another gene (including genes of viral vectors), it causes a splicing 
defect that is reversible by SSOs. Surely, no intron can be used to regulate the 
replication of the positive-strand RNA genome itself; however, defective 
introns and SSOs can be used to control the release of infectious RNA from 
DNA/RNA layered vectors. Again, as in the case of miRNA inhibitors, the main 
hurdle is likely to be that the approach demands the co-delivery of viral 
constructs and SSOs. How will SSOs validated for clinical use for this purpose 
been developed? Does obtaining such SSOs drastically increase the cost of 
technology? Such risks certainly exist, and it would hinder the development of 
clinically validated SSOs for such use.  
The diseases curable by splicing corrections include Duchenne muscular 
dystrophy, an X-chromosome linked recessive muscle-wasting disease caused 
by nonsense mutations in the dystrophin gene. Although there is currently no 
treatment for Duchenne muscular dystrophy, promising approaches such as 
exon-skipping therapy could be applied to this disease. This approach is similar 
to the use of splice correction technology: ASOs are used to block splicing sites 
flanking exons which contain premature stop codons and thus eliminate such 
exons from the mRNA coding for dystrophin protein. Like splice-switch 
technology, this approach can also be adapted for use with DNA/RNA layered 
vectors of RNA viruses. The possible benefits of the method are obvious: two 
exon-skipping oligonucleotides are already in late stages of clinical trials, one 
(Eteplirsen) in phase II and one (Drisapersen) in phase III; at least one 
additional compound, PRO044, is in phase I/IIa. Thus, it can be envisioned that 
therapeutic compounds developed to treat genetic disorders that have nothing in 
common with viruses may one day be used to regulate the rescue of RNA 
viruses from DNA/RNA layered vectors and/or in other virotherapies. Although 
this is not likely to happen soon, it does not hurt to think big. 
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RESULTS AND DISCUSSION 
 
Objectives of the present study 
This thesis is based on three logically connected research projects (I, II, III), 
which were undertaken with following general aims: 
1. To identify the reason for the instability of plasmid containing cDNA of 
RNA-launched full-length SFV4-based vector in E. coli and, based on this, 
to develop a highly stable DNA/RNA layered plasmid construct usable as a 
platform for the subsequent development of different SFV4-based full-
length vectors.  
2. To develop full-length SFV4-based DNA/RNA layered vectors in which the 
rescue of infectious RNAs is controlled by the use of splice-switching 
technology and to characterize the obtained vectors in cell culture assays.  
3. To develop full-length SFV4-based DNA/RNA layered vectors in which the 
rescue of infectious RNAs and the subsequent spread of rescued virus is 
controlled by cellular miRNAs and to evaluate different strategies of 
miRNA target site construction and insertion in the vector genome using 
cell culture assays. 
Each general aim encompassed a number of specific aims; these are highlighted 
in the subsequent sections. 
 
 
General rationale of the studies 
The RdRps of RNA viruses lack proofreading activity and are prone to switch 
between homologous RNA templates (copy-choice recombination). For vectors 
based on such viruses, this inevitably results in the production of heterogenous 
progeny, competition between different genotypes and subsequent evolution. 
Through these processes, changes that reduce the fitness of the genome are 
eliminated sooner or later (Rausalu et al., 2009). Unfortunately, most if not all 
changes made during the construction of RNA-virus-based vectors fall within 
the category of “unfavorable”. Duplication of SG promoters interferes with 
natural gene expression, while insertion of IRES elements or genes of interest 
increases the size of the vector genome, slows replication and (if inserts are too 
large) hampers the packaging of recombinant genomes into icosahedral NC. 
The expression of a gene of interest (with the exception of some selective 
markers, such as antibiotic resistance genes) is at best neutral for the virus; 
often, the proteins of interest are toxic to the cell or otherwise harmful to virus 
replication. In addition, the inserted sequences may contain RNA structures that 
by some (typically unknown) mechanism interfere with crucial viral functions. 
Mutations in vector genome can appear at any point in time; if they 
substantially increase the replication capacity of the vector, the mutant genomes 
can become dominant within one viral generation (Zusinaite et al., 2007). 
Hence, the stability of such vectors is an intrinsic problem. It can be alleviated 
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but never eliminated by appropriate design of the vector. Thus, inserts can be 
constructed so that they have minimal effect on the virus and/or can be inserted 
in a way that makes their elimination more difficult (Tamberg et al., 2007). It is 
also helpful to know the primary reasons for loss of any specific marker because 
this allows the researcher to minimize the damage by using appropriate 
conditions for vector production and propagation. When these approaches are 
combined with each other, and with a certain amount of luck, one may obtain an 
RNA-virus-based vector referred to as “genetically stable” (although, strictly 
speaking this is not exactly true).  
Although these very important aspects of vector design and application were 
not a primary focus of this study, their existence has had a certain impact on the 
research described here (studies I-III) and, in some cases, has promoted parallel 
projects (Rausalu et al., 2009) that are not presented as part of this thesis. 
Instead, the starting point of my work was a stability problem of a different 
type. The infectious cDNA clone of SFV4, the plasmid pSP6-SFV4, is very 
difficult to propagate. Furthermore, when the cDNA of this virus is engineered 
to produce an RNA-launched vector, the problems are further increased: 
transformed bacteria refuse to grow, and even if they do, the obtained plasmid 
more often represents a mixture of different aberrant forms than high-quality 
homogeneous material. At best, researchers are losing time and money on 
repeated purification attempts. At worst, they face a complete inability to 
perform relatively easy tasks such as construction of SFV4-based libraries Thus, 
in our studies, we were losing the stability of the plasmid vector prior to the 
rescue of replicating RNA and facing stability problems even before they “had a 
right” to appear. What was needed was a “foolproof” system that would, at the 
same time, be inexpensive, fast and convenient to use. When this research was 
initiated, there was no certainty regarding what would we end up with; as it 
happened, we obtained the DNA/RNA layered system for SFV that is intricately 
described in study I. Because this appeared very promising, it seemed 
appropriate to use it for something more elaborate; thus, largely by itself, the 
existence of this system promoted studies dedicated to the development of new 
approaches for the control and regulation of alphavirus-based vectors (studies II 
and III).  
 
 
Construction of an SFV-based plasmid without  
stability problems (I) 
The problems with stability and resulting low yields of the pSP6-SFV4 plasmid 
are known to everyone who has ever worked with this plasmid; in fact, they 
were immediately observed by the researchers who constructed it in 1991. 
Nevertheless, for a period of 15 years many research groups used this plasmid 
as a tool without attempting to discover the reasons for its disturbing lack of 
stability. However, a few observations that yielded useful information were 
made by our research group: 
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– The pSP6-SFV1 plasmid, which contains cDNA of the corresponding SFV 
replicon vector, has no stability problems. 
– The pSP6-Helper1 plasmid, which contains cDNA of the corresponding 
SFV helper-RNA, has no stability problems 
– When pSP6-SFV4 was recreated by combining fragments from pSP6-SFV1 
and pSP6-Helper1 (which became standard protocol in our lab), instability 
always appeared. 
These observations indicated that the problem was created by the presence of 
both cDNAs of ns- and structural regions in the same plasmid. It was further 
observed that all attempts to substitute the SG promoter sequence in pSP6-
SFV4 or even in pSP6-Helper1 for the sequence corresponding to IRES of 
EMCV failed while the same manipulation could be easily done in pSP6-SFV1. 
The cDNA of EMCV IRES is known to contain sequences that function as 
promoters for bacterial RNA polymerase. Thus, the following hypothesis was 
proposed: the cDNA corresponding to the ns-region of the SFV genome (more 
precisely, the region of cDNA that is absent in the pSP6-Helper1 plasmid) 
contains sequences that function as weak promoters in bacterial cells. This 
results in the production of cryptic transcripts that are translated by bacterial 
ribosomes to viral proteins, one or more of which are toxic to E. coli. It was also 
obvious that the sequence containing the promoter-like regions must be among 
the sequences coding for the structural proteins of SFV4 as pSP6-SFV1, which 
lacks corresponding regions also lacks stability problems. 
Initial attempts to detect expression of SFV structural proteins in E. coli 
transformed using pSP6-SFV4 failed; the only antibody available to us was an 
antibody against C-protein that because it was raised against E. coli-expressed 
C-protein, gave a background signal that was too high. The only useful piece of 
information obtained from this experiment was that the expression of viral 
structural proteins, if it takes place, must occur at a low level. Therefore, 
another approach based on the interruption of the structural ORF by insertion of 
nonsense mutations at various positions was used (I, Fig. 1). This approach 
provided clear-cut results: all such mutations drastically reduced or completely 
eliminated the instability of the plasmid in E. coli. Analysis of the growth of 
transformed bacterial cultures revealed that toxicity was associated with cryptic 
expression of viral glycoproteins, especially E1. The reason for cryptic 
expression was obviously the presence of one or more weak bacterial promoters 
in cDNA corresponding to the ns-region of SFV4. Interestingly, cDNA of 
another SFV isolate, SFVA7(74), apparently lacks such elements; the plasmid 
corresponding to that isolate is extremely stable in bacteria. This provided a 
relatively easy means of mapping the region responsible for the effect and could 
allow us to eliminate the promoter(s) and the problems they caused by using 
silent mutagenesis. However, although such work can teach us something about 
bacterial transcription, this work would contribute nothing to our understanding 
of the molecular biology of alphaviruses. Furthermore, it had the potential to 
hamper the use of the resulting clones in basic studies. In the case of small RNA 
viruses, the secondary structure of the genome, which will inevitably be 
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changed by silent mutagenesis, may contain information that is essential for the 
viral infection cycle. Loss of or changes in this information may not be harmful 
in the context of the design and use of SFV-based vectors, but it is not 
acceptable for studies of SFV molecular biology and pathogenesis. These 
considerations argued against the use of this approach to solve the instability 
problem. 
An alternative approach to the problem involves blocking the expression of 
structural proteins in bacterial cells. There are various ways to accomplish this. 
For example, regulatory elements, such as sequences that bind to the 
bacteriophage MS2 capsid protein, can be added to the construct. Binding to the 
capsid protein of MS2 would certainly suppress translation from the cryptic 
mRNAs. However, because it results in the modification of viral RNA, the 
addition of regulatory elements could again be used in the context of vector 
development but not in constructs designed for basic studies of SFV replication. 
To make the plasmid vector suitable for both applications, an approach that 
does not involve modification of the viral RNA is needed. One such approach, 
which is actually well known and is often used in the development of RNA 
virus-based DNA/RNA layered systems, is interruption of the viral reading 
frame(s) by insertion of intron(s). Because introns are completely removed by 
splicing, this approach will produce no alternation in the replicating viral RNA. 
Thus, it was decided to re-engineer the unstable pSP6-SFV4 plasmid into a 
DNA/RNA layered plasmid in which the expression of the viral structural 
proteins could be blocked by intron insertion (I, Fig. 2). To trigger the synthesis 
of SFV RNA in mammalian cells, the constructed cDNA plasmid contained a 
CMV promoter; simian virus 40 polyadenylation signal and hepatitis D virus 
negative strand ribozyme were used to terminate RNA synthesis and to trim the 
transcript so that it ends in a poly(A) sequence without any extra 3’ nucleotides. 
Most importantly, an intron from rabbit β-globin gene was inserted within the 
cDNA region encoding C-protein. This location was chosen because it allowed 
blocking of expression not only of E1 but of all glycoproteins of SFV. It was 
also chosen so that the eukaryotic transcripts, unless spliced correctly, would 
have defects that were as severe as possible to avoid the expression of large 
amounts of truncated glycoproteins in the transfected cells. Nevertheless, the 
selection of the insertion site involved a fair amount of guessing, and the 
possibility that the construct needed to be re-designed, possibly more than once, 
was considered. However, such drastic measures were unnecessary because 
interruption of the reading frame in the capsid region resulted in complete 
elimination of instability problems with this vector in bacteria; the modified 
plasmid vector was able to multiply to a high copy number. Furthermore, 
problems associated with the rescue of the virus in cell culture were not 
observed in this study or by other research groups who have been using this 
construct for nearly five years.  
The first critical issue to be determined for new virus-based infectious 
constructs is the efficiency of rescue of infectious virus from the vector 
(hereafter, the term “infectivity” is used to designate this efficiency). In the case 
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of rescue of wt virus, it does not really matter how many cells are actually 
infected by delivery of the DNA/RNA layered plasmid; the rescued virus 
spreads, and ultimately all cells will be infected. However, the situation is very 
different for studies involving the analysis of mutant viruses. Many mutations 
that severely reduce the infectivity of SFV RNA have been described. In 
general, mutations that later are reverted, pseudoreverted or compensated tend 
to reduce the infectivity of RNA-launched constructs as much as 10,000-fold. 
Thus, unless the infectivity of the original construct exceeds 104 plaques/µg of 
plasmid, such mutations will inevitably (and mistakenly) be classified as lethal 
mutations (Zusinaite et al., 2007; Lulla et al., 2012). Similarly, if one’s aim is 
the construction of virus-based libraries, their representativity (the number of 
different virus variants in the library) will be directly proportional to the 
infectivity of the vector plasmid used. Hence, the availability of a construct with 
high infectivity is crucial for both of these applications. Using the infectious 
center assay (ICA), it was found that the infectivity of the layered vector for 
BHK-21 cells (which, to our knowledge, are the most susceptible host cells for 
SFV) was 1x105 plaques/µg of plasmid DNA. Compared with transcripts 
derived from the RNA-launched vector, the infectivity of the new DNA plasmid 
(now designated pCMV-SFV4) was approximately 5-fold lower; however, its 
infectivity exceeded that of the SINV-based DNA/RNA layered vector 
(Dubensky et al., 1996) by almost 10-fold. In addition to its slightly lower 
infectivity (compared to RNA transcripts), it was also found that infection 
launched using the pCMV-SFV4 vector was delayed by approximately 1 hour 
compared to RNA-launched infection (I, Fig. 2). This lag time can be explained 
by the fact that, unlike infectious RNA transcripts, a DNA vector must enter the 
nucleus of the host cell and initiate the synthesis of future RNA genomes and 
the viral RNAs must be transported back to the cytoplasm, processes that 
require additional time.  
The second critical issue associated with the use of DNA/RNA layered 
vectors with inserted introns is the possibility of formation of defective 
genomes. In the case of pCMV-SFV4, the intron is inserted into the sequence 
corresponding to the structural region of SFV. Irrespective of splicing events, 
the transcripts of this DNA/RNA layered vector will be capable of producing 
virus replicase proteins, and viral RNA replication will occur. Furthermore, 
such RNAs can also be packed into virions if the cell also contains wt RNA 
genomes that can be used to produce structural proteins. Because the cDNA of 
SFV4 contains numerous cryptic splicing sites, it is possible that incorrect 
splicing could also occur; for example, one correct splicing site (from the 
inserted intron) and one incorrect splicing site (a cryptic site from the cDNA) 
might be used. Again, this could result in the production of defective but 
replication-competent (at least in the presence of correct transcripts) RNAs. 
Both of these unwanted events can be minimized by elimination of cryptic 
splicing sites from the cDNA of SFV by means of silent mutagenesis. However, 
this situation again involves the use of RNA modifications that are not 
acceptable in studies of SFV molecular biology and/or pathogenesis. Thus, 
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there was a real possibility that cells transfected with pCMV-SFV4 would 
contain two different types of vector-derived RNAs: correctly spliced products 
and incorrectly spliced RNAs that co-replicate, both of which are packed into 
virions. If so, the presence of defective genomes could represent a significant 
problem. For a single virus or vector, serial plaque purification or low-MOI 
passages can be used to eliminate such defective genomes; however, these 
methods cannot be used when producing virus-based libraries or to propagate 
vectors with a tendency to instability (loss of inserts). Hence, it was important 
to determine whether formation of defectively spliced modified genomes 
represents a problem for pCMV-SFV4. To clarify the matter, RT-PCR and 
western blot analysis were performed. RT-PCR analysis revealed that virus 
stocks rescued from pCMV-SFV4 did not contain detectable levels of 
contaminating un-spliced or incorrectly spliced RNA. Western blot analysis 
revealed that all ns-proteins of the virus rescued from pCMV-SFV4 were of the 
correct size, and no aberrant forms of these proteins were observed. The only 
defect observed following the use of this method was that in addition to 
recognition of a prominent C-protein of the correct size, the corresponding 
antibody also recognized a smaller product that was not observed in cells 
infected with wt SFV4 (I, Fig. 3). The origin of this product is unclear; we 
could not detect defective RNAs that could serve as templates for its synthesis. 
It was therefore concluded that the removal of the inserted intron is correct and 
virtually complete. These results show that un-spliced or incorrectly spliced 
RNAs are either absent from this system or present at levels below the level of 
detection and that they do not represent an obstacle to the use of pCMV-SFV4 
or other DNA/RNA layered vectors that are based on this construct. 
Thus, the aims of the first study were fully met; in all analyzed aspects, pCMV-
SFV4 performed even better than was originally hoped. This success also 
provided a very efficient tool for our research group and for many other 
research groups. We have provided the plasmid to more than ten laboratories all 
over the world, who are now using it instead of pSP6-SFV4 plasmid. Of note, 
our laboratory has continued to use the older plasmid in addition to the novel 
one, especially in applications that do not require insertion of additional genes 
but require initial infectivity to be as high as possible. We have also never 
managed to replace RNA-launched SFV replicon vectors with DNA/RNA 
layered vectors: the yields of VRPs achieved using RNA-launched constructs 
remain superior to those obtained through the use of DNA/RNA layered 
vectors. Thus, there is clearly room to improve the technology, both with 
respect to vectors and with respect to their delivery. Regarding the latter, special 
studies have been performed in collaboration with a research group working on 
the development of novel transfection reagents (Pärn et al., 2013). Studies II 
and III of this thesis are also based on the use of pCMV-SFV4. However, these 
studies took another turn: the focus was shifted to the problem of whether and 




Use of splice-switch technology to regulate rescue  
of replicating RNA from full-length DNA/RNA layered 
SFV vectors (II) 
The previous study revealed that introduction of a single intron into full-length 
infectious cDNA of SFV4 carried a number of important consequences: the 
vector plasmid became more stable, its infectivity became superior to that of 
other described DNA/RNA layered vectors of alphaviruses, and no adverse 
effects on the rescue of replicating RNA were observed. An obvious extension 
of this study was to attempt to introduce additional introns into the pCMV-
SFV4 plasmid. This could be accomplished, but no further increase in infec-
tivity was observed. This led us to consider whether the introns can be used for 
the opposite purpose – to negatively regulate the infectivity of the DNA/RNA 
layered vector in controlled manner. In parallel studies, it was shown that 
defective introns, specifically the second intron of the human β-globin gene, 
which in some individuals carries mutations associated with β-thalassemia, can 
be used to suppress the expression of firefly luciferase (Luc) if the 
corresponding gene is integrated into the genome of the cell or delivered into 
the cell using recombinant adenovirus vectors. Importantly, in both cases, it was 
shown that this effect could be reversed using SSOs that target the aberrant 
splicing sites within the intron. Thus, the idea and also a tool-set that includes 
the wt second intron of the human β-globin gene (control), three aberrantly 
spliced introns associated with the β-thalassemia that contain point mutation at 
positions 654 or 705 and an artificially constructed intron containing both of 
these mutations, as well as SSOs capable of rescuing defects caused by these 
introns, were available for use. It was also realized that to be efficient aberrantly 
spliced introns must be inserted into the region corresponding to the ns-region 
of SFV because only then will their aberrant splicing result in the production of 
RNAs that cannot be used to produce functional replicase. Furthermore, it was 
realized that this approach can be used only to control the rescue of RNA 
genome of the vector. Thus, unlike the case of adenovirus vectors, there is no 
reversal of the virus infection. It is also obvious that the effects of inserted 
introns and SSOs on the DNA/RNA layered vector of SFV will be qualitative 
because one cannot obtain “partially infected” cells. Hence, it was assumed that 
to achieve efficient control over such vectors, the insertion of more than one 
aberrantly spliced intron may be required. Therefore, a set from 11 different 
full-length DNA/RNA layered SFV vectors was constructed. All of these 
vectors contained a Luc-encoding sequence inserted into the nsP3 region of 
SFV. The sites used for the insertion of wt or aberrantly spliced introns were 
selected in the region encoding Luc (the same sites were previously used in 
adenovirus vectors) and in the region encoding nsP4 (II, Fig. 1, Table 1). 
Hence, aberrant splicing of any of such introns will prevent expression of 
functional nsP4 and thus prevent replication of the produced RNA. However, 
aberrant splicing of the intron within nsP4 would have no effect on the 
expression of Luc from primary transcripts made using the CMV promoter. 
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This set of vectors was first tested for efficiency of rescue of replication-
competent RNA using the ICA method. It was confirmed that insertion of one 
or two wt introns into the full length DNA/RNA layered vector of SFV4 did not 
have a negative effect on the infectivity of the vector in BHK-21 or HeLa cell 
lines; no increase in infectivity was observed either (data not shown). Thus, the 
insertion of additional wt introns did not affect the infectivity of the vector. 
When the same analysis was performed using vectors with aberrantly spliced 
introns and BHK-21 cells, various levels of inhibition of infectivity were 
observed (II, Table 2). First, it was found that insertion of an intron with a 
mutation at position 705 into the Luc region reduced infectivity approximately 
two-fold. Insertion of an artificial intron harboring two mutations resulted in a 
five-fold reduction in recombinant virus rescue. The insertion of two aberrantly 
spliced introns with similar or different point mutations was even more effi-
cient; in this case, the infectivity of the vector was reduced ten-fold. The largest, 
nearly fifty-fold, reduction in infectivity was achieved with the use of two 
artificial introns. The ICA performed with HeLa cells yielded less information 
because no plaques were obtained for any construct containing an aberrant 
intron or combination of introns. The detection limit of standard ICA is, 
however, in the range of 10 plaques/μg DNA, and reliable quantification of 
results requires efficiency to be at least several-fold higher than this. Because 
vectors containing aberrantly spliced introns failed to reach such efficiencies, 
we took advantage of a more sensitive assay based on the measurement of 
vector-mediated Luc expression. This analysis revealed tendencies similar to 
those found for BHK-21 cells using ICA (II, Fig. 4).  
Thus, it could be concluded that aberrantly spliced introns can be used to 
block rescue of replication-competent RNA from the DNA/RNA layered SFV 
vectors. While insertion of a single intron had a modest effect, two such introns 
acting in a synergistic manner increased the overall effect. Though it was not 
experimentally verified, this observation leads to the suggestion that further 
increases in the number of aberrantly spliced introns will further increase the 
effect. Thus, insertion of introns with β-thalassemia-associated mutations into 
DNA/RNA layered vectors can reduce and very likely ultimately block the 
rescue of infectious RNA genomes from the full-length DNA/RNA layered 
vector of SFV. 
Thus far, the results shown in this section demonstrate that we have 
developed a novel and sophisticated way to “kill” the viral vector, but the real 
challenge is to regulate it. Therefore, the most important part of this project was 
to test whether it is possible to restore the infectivity of constructed splice 
defective vectors to some essential level.  
It was known that the aberrant splicing pattern caused by a single point 
mutation in the β-globin intron (either the T705G or the C654T mutation) can 
be reverted to normal by use of the corresponding SSOs (Svasti et al., 2009). 
Indeed, it was observed that the infectivity of DNA/RNA layered vectors 
containing just one mutant intron of such type was efficiently restored by the 
corresponding SSO. These data, however, are not especially useful because 
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such vectors also had relatively high infectivity in the absence of SSOs and thus 
present little practical value. Hence, the truly important point was to discover 
whether a combination of SSOs can be used to rescue the infectivity of vectors 
containing several aberrantly spliced introns. Such experiments were therefore 
performed. The obtained data convincingly demonstrated that the infectivity of 
vectors carrying two defective introns of natural origin or even of those carrying 
two artificially created defective introns was efficiently restored. Thus, the 
greater the inhibitory effect caused by the presence of aberrantly spliced introns, 
the larger was the rescue efficiency achieved through the use of a combination 
of SSOs (the largest increase documented was nearly 100-fold; II, Fig. 6). It 
was also observed that in all experiments the SSO binding to the region near 
position 654 had higher rescue efficiency than the SSO targeting the sequence 
near position 705. Furthermore, SSO 654 could also increase the infectivity of 
vectors containing aberrantly spliced introns with point mutations only at 
position 705; the opposite effect, rescue of the defect caused by mutation in 
position 654 by SSO 705, was never observed. Therefore, there are strong 
reasons to believe that SSO 654 has at least two different activities: first, it can 
block aberrant splicing site 654 and act as a standard SSO; second, its binding 
to its target per se enhances correct splicing of the mutant intron. This type of 
effect has not been previously described for this compound; however, splicing-
enhancing activity has been described, for example, for ASO binding region 
near position 632 (Resina et al., 2007; Svasti et al., 2009). It could therefore be 
assumed that the very high rescue efficiencies observed in this study (II, Fig. 6) 
resulted from the splice-switch activities of both SSOs and were enhanced by 
the splicing-enhancing properties of SSO 654.  
To summarize, the obtained results demonstrated that aberrantly spliced 
introns and SSOs can be used to regulate virus-based vectors. This technology 
was more efficient in cases of suppression and rescue of adenovirus-mediated 
gene expression (study II). It is reasonable to assume that the same type of 
regulation could also be achieved for other DNA viruses replicating in the 
nucleus, such as herpesviruses. Clearly, for these viruses the technology is not 
limited to the control of expression of a single gene; aberrantly spliced introns 
can be used to manipulate the expression of key regulatory proteins such as S13 
E1A of adenovirus or ICP4 of HSV, and therefore entire infection cycle of the 
virus can be controlled. Furthermore, DNA viruses are genetically more stable 
and less prone to eliminate inserted sequences than viruses with RNA genomes. 
Therefore, the technology could have excellent potential in the field of DNA 
virus-based vectors. The extension of this approach to the DNA/RNA layered 
vectors of alphaviruses has an obvious limitation: only rescue of infectious 
RNA genomes, but not their subsequent replication and spread, can be 
controlled. Nevertheless, this approach offers important benefits that alternative 
approaches do not. For example, unlike regulation based on the use of ts-
mutants (good technology on its own, but largely restricted to cell culture), it 
can also be used in in vivo applications. Another benefit of the method is that 
unlike other mutations introduced into the RNA genome, the aberrantly spliced 
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introns are only part of the DNA/RNA layered vector and not of the replicating 
RNA genome; hence, they do not affect RNA replication.  
The major limitation of this technology is that it requires a target (a virus 
with a DNA genome or a DNA/RNA layered vector) and its co-factor (SSO) to 
be co-delivered. While infection with DNA virus is relatively straightforward, 
efficient co-delivery of DNA/RNA layered vectors and SSOs is not, especially 
under in vivo conditions. Thus, the applicability of this approach depends on the 
development of specific (to organs, cell types, cancers) and highly efficient 
delivery technologies. Our attempts to develop one such approach are presented 
in an independent publication (Pärn et al., 2013) that is not included as part of 
this thesis. Some promising results were obtained; however, there certainly 
remain a long way to go and a number of problems that must be solved. 
Partially due to these reasons, another study addressing an alternative option for 
the regulation of viral vectors was initiated. Because the main hurdles revealed 
in study II are the delivery of SSOs and the lack of post-rescue control over 
viral RNA replication, a natural question was: do cells naturally (thus, in 
general, no delivery is required) contain any molecules that could be used to 
control the rescue of viral RNA genomes from DNA/RNA layered vectors and, 
ideally, also to control their subsequent replication and spread?  One such 
possibility was exploited and analyzed in study III. 
 
 
Rescue of recombinant virus from DNA/RNA layered 
vectors and subsequent spread of infection can be 
controlled using miRNAs (III) 
As described above, different methods of controlling virus replication have been 
developed. These methods are usually applicable only to a specific virus and/or 
have significant limitations. For example, ts-mutations are specific for each 
virus and have limited (if any) use in vivo. Insertion of conditionally toxic genes 
such as TK can increase the safety of different viral vectors, including 
alphavirus-based vectors (Tseng et al., 2009); however, the use of this approach 
is hampered by vector instability, which would greatly increase if selective 
pressure (in this case ganciclovir) were to be applied. Changes in the natural 
tropism of a virus by specific modification of its antireceptor(s) represent, at 
least in theory, an excellent approach. However, in practice its use is limited by 
the fact that viral proteins, including antireceptors, have multiple functions, 
many of which are not known. Therefore, modification of antireceptors is 
typically unfavorable for the virus, and introduced changes are therefore often 
rapidly reverted. In the case of DNA viruses, advantage can be derived from the 
available tools used to regulate or modify gene expression; for RNA viruses, 
such options are extremely limited. Thus, there is a clear need to develop 
approaches that do not suffer from the limitations described above. Therefore, it 
is not surprising that the potential of using cellular miRNAs has attracted the 
attention of a number of researchers. 
45 
The possibility of using miRNAs is based on their diversity. Some miRNAs 
are ubiquitously expressed, but there are also miRNAs with remarkable tissue 
specificity of expression. Furthermore, the panels of miRNAs expressed in 
normal and cancer cells are different; the expression of miRNAs involved in 
regulation (repression) of the cell cycle is suppressed in tumors (Chen, 2005). 
As discussed above, the construction of viral vectors positively regulated by 
miRNA is complicated. That leaves the possibility of using miRNAs as 
negative regulators by adding their target sites to virus genomes (RNA viruses) 
or transcripts. The diversity of miRNAs offers relatively straightforward 
possibilities for construction of viral vectors that are restricted from some cell 
types. This type of approach had been used in the development of lentivirus, 
HSV (Brown et al., 2006; Lee et al., 2009) and  RNA virus-based vectors 
(Barnes et al., 2008; Kelly et al., 2010), including a few vectors based on 
alphaviruses (Kamrud et al., 2010b; Ylösmäki et al., 2013). The designs used in 
the majority of these studies have been relatively similar: multiple targets of one 
or different miRNAs have been introduced as a cluster, and the target sequences 
have been presented in a form that allows perfect binding of miRNA. The 
obvious consequence of this is that the targeted RNA becomes cleaved by RNA 
induced silencing complex; hence the strongest repression is obtained. 
However, is the strongest response always the best? Multiple studies by 
different research groups, including ours, have demonstrated that the strongest 
selection pressure also results in the most rapid and efficient counter-response 
by the virus. Is the cleavage of viral RNA essential or not? If they have not 
completely escaped the attention of researchers, these questions have at least 
escaped discussion in published studies. Because the more subtle regulation of 
viral vectors may offer possibilities that robust suppression of its replication 
does not, these questions become central for study III of this thesis.  
A standard approach was used for the basic design of the cassette containing 
miRNA target sites: two copies of three different miRNA target sequences, 
separated from each other by short spacers, were included in each cassette. The 
cassettes differed from each other by the selection of target sequences (cl1: let-
7, miR-17 and miR-19; cl2: miR-214, miR-143d and miR-218) as well as by 
their configuration (III, Fig. 1). The rationale behind the selection of miRNAs 
was that miR-cl1 cassettes are targeted by miRNAs expressed at high levels in 
almost all cell types; furthermore, their ability to repress alphavirus replication 
was already known (Kamrud et al., 2010b). The miR-cl2 cassette, on the other 
hand, consists of targets of miRNAs that are absent or underexpressed in 
cervical cancer cells and was designed with the aim of studying the possibility 
of restricting virus replication in non-tumor cells. In addition to the standard 
configuration of miRNA targets, which is referred to as “Perfect” due to the 
formation of perfect duplex between miRNA and this type of target, two 
alternatives were also tested. In the configuration referred to as “Native”, 
naturally occurring miRNA target sites were used. In the configuration referred 
to as “Sponge”, a segment of the target sequence essential for cleavage was 
mutated. It was expected that both Native and Sponge targets would allow 
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binding of the respective miRNAs but that cleavage of the targeted RNA would 
not occur; instead, it was assumed that the translation of targeted RNA would 
be silenced. With one exception, the target cassette was always inserted into the 
3`-UTR region of the targeted RNA because this is the region in which most 
natural targets of miRNAs are located.  
Gene expression mediated by DNA/RNA layered alphavirus vectors results 
from a combination of two different processes. At the first step, transcription of 
replication- competent RNA from the DNA plasmid occurs. At the second step, 
cytoplasmic RNA replication and transcription is initiated. Accordingly, the 
effect of miRNAs on these processes should differ as well. At the first step the 
production of new RNA transcripts from the DNA template is not affected by 
miRNAs but the fate of the products of this reaction is. At the second step, 
binding of miRNA to the RNA genome of the virus could result in its 
destruction or in translational silencing; thus, both the production of new RNAs 
and the RNA products could be affected by miRNAs. At the same time one 
should keep in mind that alphavirus RNA replication is very efficient and is 
associated with shut-down of cellular transcription and translation. Thus, the 
production of components essential for functioning of the miRNA system 
becomes inhibited. Finally, because viral replication is highly error-prone, 
mutations that provide resistance to miRNA-mediated repression will inevitably 
occur, and the percentage of such mutants in the population will rapidly 
increase due to their selective advantage. Therefore, to obtain a better idea of 
exactly which processes are affected by miRNAs, two types of vectors were 
constructed and tested: DNA/RNA layered full-length SFV vectors and standard 
plasmid-based transient expression vectors. To make these two systems as 
similar to each other as possible, both were engineered to produce mRNAs with 
the same non-coding regions (corresponding to the UTR-s of SFV4) and 
containing the same marker, Gaussia luciferase (Gluc). The insertion sites of 
the miRNA target cassettes were also identical; they were placed between the 
Gluc encoding sequence and the 3’ UTR of the virus (III, Fig. 2A).  
It was found that in the context of the non-viral vector, all used strategies 
resulted in reduction of Gluc expression. The extent of the effect depended on 
the type of inserted cassette. In all tests, miR-cl1 had a much greater effect than 
miR-cl2, further indicating that the abundance and/or effectiveness of miRNAs 
targeting miR-cl2 was much lower than that of miRNAs targeting miR-cl1 
cassettes. It was also observed that repression of Gluc expression depended on 
the configuration of the target sequences used; perfect cassettes always caused 
more prominent repression. The insertion of the most efficient miR-cl1 perfect 
cassette resulted in nearly 200–fold reduction in Gluc expression compared to 
the non-targeted vectors, and its effect was very similar in BHK-21 and HeLa 
cells. The effects of using miR-cl1 cassettes of sponge and native design were 
less prominent and depended on the cell type: up to 10-fold reduction of Gluc 
expression was observed in BHK-21 cells, while several-fold more efficient 
repression was observed in HeLa cells. The miR-cl2 cassettes were always 
much less efficient; for these sequences, the difference between cassettes of 
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perfect design and the other two design types was also much less pronounced. 
Similarly, the repression efficiency was less dependent on the cell type (the 
effect in HeLa cells was only slightly greater) (III, Fig. 2). These data con-
firmed that repression based on silencing of mRNA translation is less efficient 
than repression based on cleavage of targeted mRNA. The different levels of 
repression observed in different cell types may result from different abundances 
of miRNAs in different cells and/or from different efficiencies of miRNA-based 
systems in these cell types. Unexpectedly, the miR-cl2 cassette was no more 
cell-type-specific than the miR-cl1 cassette. This finding indicated that 
miRNAs, target sites of which were introduced in this cassette, have low 
abundance/efficiency in both cell types.  
To our knowledge, the efficiencies of identical miRNA target sites inserted 
into standard expression constructs and these inserted into DNA/RNA layered 
full-length vectors have never been directly compared. Due to the spread of 
virus infection, comparison of levels of marker protein activities is valid only at 
early times post-transfection (as was performed in study II) and is therefore not 
a method of choice. Therefore, the efficiencies of miRNA targets in the context 
of SFV DNA/RNA layered vectors were analyzed using ICA. It was found that 
all the constructed cassettes reduced infectivity of the vectors, although in many 
cases the effects were small and not statistically significant. In BHK-21 cells, 
miR-cl1 cassettes of sponge and native design provided modest (2-fold) effects, 
while the cassette of perfect design caused a massive (approximately 2500-fold) 
reduction in infectivity. In HeLa cells, the miR-cl1 cassette of perfect design 
completely blocked rescue of infectious virus; no plaques were detected using 
ICA, and no Gluc expression or infectious virus release was detected in 
transfected cell cultures. Surprisingly, however, plaques were rarely detected in 
HeLa cells transfected with vectors containing miR-cl1 cassettes of native and 
sponge design, although for these constructs the rescue of infectious virus, 
which was shown by both Gluc expression and the release of infectious virions, 
was always observed. At a rough estimate, these cassettes caused approximately 
200-fold reduction of infectivity of recombinant vectors in HeLa cells; thus, the 
extent of repression was approximately 100-fold greater in HeLa than in BHK-
21 cells. This difference cannot be solely attributed to the different abundance/ 
efficiency of corresponding miRNAs in these cell lines because differences 
observed using expression- plasmid-based vectors were only two-to-three fold. 
However, the situation was strikingly similar to that observed for vectors 
containing single copies of aberrantly spliced introns (study II). In that case, the 
insertion of aberrantly spliced introns also reduced plaque formation in BHK-21 
cells (ICA) by approximately two-fold but completely blocked it in HeLa cells. 
Thus, it is reasonable to assume that in BHK-21 cells, which are extremely 
permissive for alphavirus replication, the effects caused by various repressors 
are much smaller than those observed in less permissive cells. One can also 
assume that the most sensitive step in the process of rescue of virus from 
DNA/RNA layered vector is likely the establishment of replication, as this is the 
only thing in common between vectors containing aberrantly spliced introns and 
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these with inserted miRNA target sites. However, it cannot be ruled out that 
differences in sensitivity also exist at the subsequent stages of alphavirus 
infection. Therefore, BHK-21 cells may not represent an ideal test system for 
alphavirus-based vectors because with these cells there is a possibility of critical 
underestimation of the potency of repressors of alphavirus replication. Notably, 
however, BHK-21 cells are the only cell line that can be used in some cases. 
Thus, here we also attempted to compare the effects caused by miR-cl1 
(perfect) cassettes inserted in the 3’-UTR region to those caused by insertion of 
similar cassettes into the ns-region of the viral vector. The vectors used for the 
latter strategy were engineered to contain an additional marker (III, Fig. 3A) 
and, presumably due to their increased size, had infectivities that were 
approximately 200-fold lower than those of vectors lacking the second marker. 
These levels of infectivity were too low to be reliably measured in any cells 
other than BHK-21. Using these cells, it was found that insertion of the miR-cl1 
perfect target resulted in an additional 7-fold reduction in infectivity; the effect 
was significant but much smaller than that achieved by insertion of essentially 
the same target into the 3’ UTR region. Thus, based on the results of this study 
and that of Kamrud and colleagues (2010), it can be concluded that the 3’ UTR 
of alphaviruses is the most favorable position for miRNA target insertion, at 
least when the highest repression efficiency is desired. The finding that the 
effects of miR-cl2 target insertion at the very same position were relatively mild 
in both cell types tested (at best, approximately 4-fold repression was achieved 
using an miR-cl2 cassette of perfect design in HeLa cells) confirms that the 
efficiencies of the corresponding miRNAs in both cell lines must indeed be very 
low. 
Similar to the case with vectors containing aberrantly spliced introns, 
achieving the strongest miRNA mediated repression is not the most important 
goal. What is needed is efficient and, importantly, stable control over the vector. 
It was expected that vectors with miR-cl1 of perfect design may well represent 
an example of strong but unstable repression and that such vectors would most 
likely require the presence of miRNA inhibitors to replicate to high titer. This 
was experimentally verified using BHK-21 cells transfected with miRNA 
inhibitors or irrelevant oligonucleotides (SSO 705, used in study II, was used 
for this purpose; the choice was based on the finding that this oligonucleotide 
has no effect on the rescue and replication of SFV). It was observed that, 
compared to the non-targeted control vector, the rescue of targeted RNA 
genomes occurred after a delay; however, the corresponding virus replicated to 
high titer regardless of the presence of miRNA inhibitors (III, Fig. 4). The 
ability to express a Gluc-marker did, however, clearly depend on the presence 
of these inhibitors, leading to the conclusion that in the absence of the inhibitors 
deletions covering the region encoding Gluc (and most likely also the miR-cl1 
target) must have occurred. Subsequent analysis performed using northern 
blotting (III, Fig. 5) and RT-PCR followed by sequencing clearly revealed that 
this was indeed the case. Somewhat surprisingly, it was observed that similar 
deletions also occurred in the genomes of virus propagated in the presence of 
49 
miRNA inhibitors. This finding indicates that selection pressure against miR-
cl1 perfect cassette was clearly too great to allow the corresponding construct to 
remain genetically intact even in the presence of the miRNA inhibitors. Thus, 
very prominent repression of infectivity clearly had a downside, and the 
corresponding constructs used in this part of the study, although of academic 
interest, may have very little practical value. The same is likely the case for all 
constructs targeted by the ubiquitous miRNAs present in the majority of cells.  
When planning the experiments described in this part of the thesis, more hope 
was invested in experiments with constructs containing miR-cl2 targets (in fact, 
these were the first constructs designed and tested; miR-cl1 was constructed and 
used later). The high infectivity of these constructs for the cervical cancer-
derived HeLa cell line further boosted these hopes. Disappointingly, however, it 
also turned out that the virus with a perfect miR-cl2 site propagated efficiently 
in essentially every cultivated human cell line tested (data not shown). This was 
not totally unexpected because, under conditions of continuous growth in cell 
culture, many miRNAs associated with repression of the cell cycle are 
obviously downregulated. Lacking access to a reliable supply of primary human 
cells, we intended to construct cell lines over-expressing miRNA targets that 
were included in the miR-cl2 cassette. Perhaps not surprisingly, we failed in 
two cases out of three; only HeLa cells overexpressing miR-214 were obtained. 
Most likely, the failure with the remainder of these miRNAs was due to the fact 
that their overexpression was incompatible with continuous growth of the cell 
culture; thus, transiently transfected cells should most likely have been used in 
these experiments. Of note, overexpression of miR-214 had an effect on the 
cells as well, including an unexpected effect on SFV; for unknown reasons, 
these cells supported SFV replication to a lesser extent (evidenced by the slower 
replication of control virus) than normal HeLa cells. Nevertheless, with all of its 
problems, the miR-214-expressing HeLa cell line allowed us to confirm that the 
growth of targeted virus was indeed specifically reduced (III, Fig. 7), although 
the effect was not as striking as that observed for viruses containing the miR-cl1 
target. This finding led to the prediction that viruses containing the miR-cl2 
target may not suffer from instability as did those containing the miR-cl1 target. 
Indeed, after several passages of the virus in HeLa cells, all plaque-purified 
isolates were still able to express Gluc and therefore were presumed to contain 
the miRNA target as well. The use of more sensitive methods (RT-PCR 
followed by sequencing), however, revealed that all propagated stocks of the 
recombinant virus and even the initial stock harvested directly from transfected 
cells contained some viruses with genomes that lacked part of the miR-cl2 
region (interestingly, no deletions in the Gluc-encoding regions were detected in 
the case of this virus). Thus, the existence of even a small selective pressure 
against the miR-cl2 target was sufficient to cause overgrowth by and 
accumulation of mutants with growth advantages. 
Taken together, the results of this study confirm several findings that have 
already been documented in studies using picornavirus- and flavivirus-based 
vectors. In the context of vectors based on viruses with RNA genomes, the 
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primary issue is clearly the instability of recombinant genomes targeted by 
miRNAs. There is, however, reasonable hope that the impact of this instability 
is less prominent in vivo than it is in vitro; at least, this was the case with the 
stability of marker protein-encoding sequences inserted into the alphavirus 
genome (Tamberg et al., 2007). It also appears that viruses that are restricted 
from replication in the CNS performed better than the viruses used in this study; 
they were less prone to lose inserted sequences, at least while replicating in 
non-neuronal cells. However, even when combined, these considerations are 
unlikely sufficient to warrant the clinical use of such vectors; therefore, 
strategies of recombinant genome construction must be improved. One possible 
direction for such improvement, the use of native target sites for miRNAs of 
interest, is provided by this study. The benefit of this approach is that seed 
regions of miRNAs (and therefore their targets in the genomes of modified 
viruses) are only 7 nucleotides in length, over three-fold shorter than full 
miRNAs. These sequences can therefore be engineered in large numbers into 
coding region(s) of the viral genome without changing the sequence of encoded 
proteins. Certainly, some of these elements, which are scattered over the viral 
genome, appear to be in sub-optimal (or in some cases in non-usable) locations, 
but given the possibility of generating large numbers of targets, comined they 
may still produce significant effect. Most importantly, these elements cannot be 
removed by single deletions, which was found to be the most important way in 
which miR-cl1 and miR-cl2 targets are eliminated, because such removal would 
also result in the loss of sequences coding for essential viral proteins. Of course, 
the possible loss of these sequences by reversion still remains. However, given 
the large number of possible targets, complete reversion should represent a 
significant challenge even for viruses as genetically flexible as alphaviruses. 
 
 
Some further perspectives 
All of the studies described above were designed and performed with far-
reaching aims in mind. Several possibilities concerning how these studies could 
be extended and the lessons that were learned have been provided in the 
foregoing sections and are therefore not repeated here. However, it is still 
interesting to note that the basic design of pCMV-SFV4 was extended to 
infectious clones of other SFV isolates in subsequent studies: SFV A7(74) and 
recently also SFV L10 (unpublished data). For SFV A7(74), this was performed 
for completely different reasons. The SFV A7(74) icDNA clone under the SP6 
RNA polymerase promoter is completely stable in bacteria but suffers from 
another unexplained flaw: it is notoriously difficult to transcribe in vitro, as its 
RNA yield is very poor and inconsistent. Thus, the intron insertion approach 
used to solve the instability problem with the pSP6-SFV4 plasmid was 
successfully applied to the problem of a plasmid with poor transcription 
efficiency. This worked out well, and the obtained pCMV-SFVA7(74) plasmid 
is as infectious as pCMV-SFV4. In the case of both SFV4 and SFVA7(74), the 
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improvement was so impressive that once the sequence of SFV L10 isolate 
became available we did not even make an icDNA clone under the control of 
SP6 RNA polymerase promoter.  
There are certainly many possibilities for the improvement and use of the 
miRNA-mediated control techniques described in this thesis. Some of these 
options are listed above. Here, I would like to mention just a few more 
applications. The strong suppression of virus rescue and replication achieved by 
use of miRNA targets such as miR-cl1 (perfect) actually has some practical 
applications. One of these is the development of safer replicon vectors (Kamrud 
et al., 2010b), while another could be the restriction of alphavirus vectors from 
one of its hosts. This is possible because vertebrate and insect hosts of alpha-
viruses have very different sets of miRNAs. Thus, it is very likely that SFV4 
containing an miR-cl1 perfect target would replicate normally in cells of insect 
(including mosquito) origin and that there will be little selection pressure for 
removal of the miRNA target under these conditions. However, this type of 
virus represents no real value and therefore this property was never experi-
mentally tested. The opposite combination makes much more sense: a virus 
carrying a cluster of targets of mosquito-specific miRNAs would be restricted 
from replication in mosquitoes and would not spread by insect vectors. In the 
context of the development of live attenuated vaccines against medically 
important alphaviruses (CHIKV, VEEV, etc.), this offers a clear advantage. In 
addition, miRNA targeting can also be used, at least to some extent, to improve 
the immunogenicity of alphavirus vectors. It has been reported that a flavivirus 
the genome of which was engineered to contain targets for miR-124a induced 
higher levels of neutralizing antibodies than did a standard attenuated virus 
strain (Heiss et al., 2011). Without a doubt, there are also many other ways to 
interfere with the complicated interplay that occurs between host and virus, and 






This thesis is based on three studies dedicated to the development and analysis 
of infectious DNA/RNA layered clone of SFV4 and a panel of vector constructs 
based on this clone. These projects originate from a study performed with the 
aim of identifying and subsequently eliminating the reasons for the instability of 
pSP6-SFV4, a standard RNA-launched icDNA clone of SFV, in bacterial cells. 
It was found that the instability of this plasmid was caused by the toxic effects 
of SFV envelope proteins that were cryptically expressed in bacterial cells. The 
problem was eliminated by interrupting the corresponding reading frame with 
an intron; this manipulation proved to have no adverse effect on the SFV4 
rescued from the obtained DNA/RNA layered vector. Thus, this study provided 
a tool for several further studies, two of which are included in this thesis.  
A central problem hampering the medical use of alphavirus vectors is 
concern over their safety; potential safety issues associated with the use of these 
viral vectors originate from the fact that alphavirus-based vectors are very 
difficult to regulate and control, similar to vectors based on other RNA viruses. 
Two new approaches to control these vectors were tested. First, DNA/RNA 
layered vectors, in which the rescue of replication-competent RNA genome of 
SFV was controlled by aberrantly spliced introns and splice-switch oligo-
nucleotides, were designed, constructed and tested. It was shown that rescue of 
RNA genome can be efficiently inhibited and most likely even blocked by 
incorporation of increasing numbers of defective introns into the non-structural 
portions of the vector constructs. Furthermore, the delivery of splice-switch 
oligonucleotides completely or almost completely restored the infectivity of the 
vector. This novel principle is also applicable to DNA/RNA layered vectors of 
other RNA viruses and may be especially useful in controlling and regulating 
gene expression mediated by vectors constructed from viruses of DNA genomes 
that replicate in the nucleus of the cell. 
Using cellular miRNAs to target the genomes of recombinant alphavirus 
may also represent a viable method to control rescue as well as replication and 
spread of the vector. This possibility was tested using a number of viral 
constructs. It was found that repression of virus replication can be achieved by 
the insertion of different types of miRNA targets, including those naturally 
occurring in cellular mRNAs. It was also found that strong inhibition of 
recombinant virus rescue is relatively easy to achieve and that the main hurdle 
for development of miRNA controlled alphavirus vector is actually the creation 
of a vector in which the inserted targets are not lost. Based on the obtained 
results, construction of recombinant genomes containing natural targets of the 
miRNAs scattered over the coding region of the alphavirus genome is proposed 
as the best prospective approach. Such vectors, which may also be engineered 
to contain other control systems, may find be applied in the development of 
attenuated virus-based vaccines, recombinant vaccines or anti-cancer agents.  
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SUMMARY IN ESTONIAN 
 
Alfaviirustel põhinevate multifunktsionaalsete  
geeniekspressiooni ja -teraapia süsteemide väljatöötamine ja 
funktsionaalne analüüs 
Alfaviirused on positiivse polaarsusega RNA genoomiga viirused sugukonnast 
Togaviridea. Looduses levivad alfaviirused lülijalgsete vektorite abil. Selg-
roogsetel peremeestel põhjustavad nad erinevaid haigusi; Uue Maailma alfa-
viirustele on iseloomulik entsefaliidi, Vana Maailma alfaviirustele aga artriidi 
tekitamine. Enim uuritud alfaviiruste, milliste hulka kuulub ka Semliki Forest 
viirus (SFV), laboratoorsed tüved on inimesele mitte patogeensed. Kuna nende 
viiruste genoome on lihtne manipuleerida ja nende kasutamisel vaktsineerimisel 
või vähivastases teraapias (siiani loom-mudelitel) on täheldatud mitmeid kasu-
likke efekte (kaasasündinud immuunvastuse aktiveerimine, kasvaja suhtes 
olemasoleva immuun-tolerantsi murdmine) on need viirused kujunenud 
perspektiivseteks tööriistadeks geeni- ja kasvajavastaste vaktsiinide välja-
töötamisel. 
Käesolev väitekiri põhineb kolmel artiklitena avaldatud uurimisetööl mis 
kajastavad SFV genoomi cDNA-l põhineva infektsioonilise DNA/RNA kiht-
vektori ning selle alusel valmistatud rekombinantsete vektorite kavandamist, 
valmistamist ja iseloomustamist. Nende projektide alguspunktiks oli uurimus, 
mille eesmärgiks oli välja selgitada põhjused, mis muudavad pSP6-SFV4, stan-
dardse RNA kaudu käivitatava infektsioonilise klooni, bakterirakkudes genee-
tiliselt ebastabiilseks. Tehti kindlaks, et seda ebastabiilsust põhjustab SFV 
membraanivalkude soovimatust ekspressioonist tulenev toksiline mõju bakte-
rile. See probleem lahendati liites SFV lugemisraami introni, mis takistas toksi-
liste valkude tootmist bakteris kuid ei mõjutanud negatiivselt loodud DNA/ 
RNA kihtvektorist vabanenud viiruse omadusi. Seega loodi antud uurimistöö 
käigus töövahend, mida kasutati mitmetes järgnevates uurimistes. 
Keskseks probleemiks, mis on siiani takistanud alfaviirustel põhinevate 
vektorite kasutamist meditsiinis, on olnud kahtlused selliste viirustel-põhinevate 
vektorite ohutuses. See probleem tuleneb omakorda asjaolust, et sarnaselt teistel 
RNA-genoomsetel viirustel põhinevatele vektoritele on nende vektorite 
käitumist organismis väga raske kontrollida. Selles väitekirjas katsetati kahte 
uut lähenemist, mille ühiseks eesmärgiks oli seesuguse kontrolli tekitamine. 
Uue ja originaalse lähenemisena kavandati ja konstrueeriti SFV põhised DNA/ 
RNA kihtvektorid milles rekombinantse SFV genoomi vabanemist takistavad 
viiruse kodeerivasse alasse sisse viidud defektsed (valesti splaisitavad) intronid. 
Selliste valesti splaisitavate intronite poolt põhjustatud defekti on võimalik 
kompenseerida splaisingu mustrit muutvaid oligonukleotiide kasutades. Läbi-
viidud uurimistöös näidati, et mitme valesti splaisitava introni lisamine vektori 
genoomi surub efektiivselt maha (ja eeldatavasti võib ka täielikult blokeerida) 
viiruse infektsioonilise RNA vabanemist; splaisingu mustrit muutvate oligo-
nukleotiidide lisamine aga vähendab oluliselt või kõrvaldab selliste intronite 
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põhjustatud negatiivse mõju viirus-vektorile. Nendest tulemustest lähtudes võib 
väita, et antud meetod sobib ka teiste RNA-viirustel põhinevate kihtvektorite 
kontrollimiseks ja võib olla eriti efektiivne vektorite, mis põhinevad rakutuumas 
replitseeruvatel DNA-genoomsetel viirustel, kontrollimiseks.  
Raku micro-RNAde (miRNAde) kasutamine alfaviirustel põhinevate vekto-
rite mõjutamiseks kujutab endast lähenemist mille abil võib viiruse paljunemist 
kontrollida ka peale tema infektsioonilise genoomi vabanemist DNA/RNA 
kihtvektorist. Vastava uurimuse jaoks valmistatud mutantsete vektorite uuri-
mine näitas, et miRNA vahendatud kontroll viiruse vabanemise ja järgneva 
leviku üle on suhteliselt lihtsasti saavutatav; selleks on vaja viiruse genoomi 
liita raku miRNAde sihtmärk-järjestusi. Reaalseks ja palju keerulisemaks 
probleemiks osutus selliste vektorite geneetilise stabiilsuse tagamine. Saadud 
tulemuste põhjal võib järeldada, et selle eesmärgi saavutamiseks on vaja 
kasutada looduslikult esinevaid miRNAde sihtmärke mida saab suurel hulgal 
sisse viia viirusele olulisi valke kodeerivatesse aladesse. Sellised viirused, 
millele võib olla lisatud ka muid kontroll-süsteeme, võivad leida kasutust 
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